<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Curr Opin Toxicol</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr Opin Toxicol</journal-id>
<journal-title-group>
<journal-title>Current Opinion in Toxicology</journal-title>
</journal-title-group>
<issn pub-type="epub">2468-2020</issn>
<publisher>
<publisher-name>Elsevier B.V</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28066829</article-id>
<article-id pub-id-type="pmc">5193490</article-id>
<article-id pub-id-type="publisher-id">S2468-2020(16)30025-0</article-id>
<article-id pub-id-type="doi">10.1016/j.cotox.2016.10.002</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The multifaceted role of Nrf2 in mitochondrial function</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Holmström</surname>
<given-names>Kira M.</given-names>
</name>
<email>kira.holmstrom@helsinki.fi</email>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="corresp" rid="cor1">∗</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kostov</surname>
<given-names>Rumen V.</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dinkova-Kostova</surname>
<given-names>Albena T.</given-names>
</name>
<email>a.dinkovakostova@dundee.ac.uk</email>
<xref ref-type="aff" rid="aff3">3</xref>
<xref ref-type="aff" rid="aff4">4</xref>
<xref ref-type="aff" rid="aff5">5</xref>
<xref ref-type="corresp" rid="cor2">∗∗</xref>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label>BioMediTech and Tampere University Hospital, University of Tampere, Tampere, Finland</aff>
<aff id="aff2"><label>2</label>Institute of Biotechnology, University of Helsinki, Helsinki, Finland</aff>
<aff id="aff3"><label>3</label>Division of Cancer Research, School of Medicine, University of Dundee, Dundee, Scotland, UK</aff>
<aff id="aff4"><label>4</label>Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA</aff>
<aff id="aff5"><label>5</label>Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA</aff>
<author-notes>
<corresp id="cor1"><label>∗</label>Corresponding author: Holmström, Kira M. <email>kira.holmstrom@helsinki.fi</email></corresp>
<corresp id="cor2"><label>∗∗</label>Corresponding author: Dinkova-Kostova, Albena T. <email>a.dinkovakostova@dundee.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>12</month>
<year>2016</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.-->
<pub-date pub-type="epub">
<month>12</month>
<year>2016</year>
</pub-date>
<volume>1</volume>
<fpage>80</fpage>
<lpage>91</lpage>
<permissions>
<copyright-statement>© 2016 The Authors</copyright-statement>
<copyright-year>2016</copyright-year>
<license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
</license>
</permissions>
<abstract id="abs0010">
<p>The transcription factor nuclear factor erythroid 2 p45-related factor 2 (Nrf2) is the master regulator of the cellular redox homeostasis. Nrf2 target genes comprise of a large network of antioxidant enzymes, proteins involved in xenobiotic detoxification, repair and removal of damaged proteins, inhibition of inflammation, as well as other transcription factors. In recent years it has emerged that as part of its role as a regulator of cytoprotective gene expression, Nrf2 impacts mitochondrial function. Increased Nrf2 activity defends against mitochondrial toxins. Reduced glutathione, the principal small molecule antioxidant in the mammalian cell and a product of several of the downstream target genes of Nrf2, counterbalances mitochondrial ROS production. The function of Nrf2 is suppressed in mitochondria-related disorders, such as Parkinson's disease and Friedrich's ataxia. Studies using isolated mitochondria and cultured cells have demonstrated that Nrf2 deficiency leads to impaired mitochondrial fatty acid oxidation, respiration and ATP production. Small molecule activators of Nrf2 support mitochondrial integrity by promoting mitophagy and conferring resistance to oxidative stress-mediated permeability transition. Excitingly, recent studies have shown that Nrf2 also affects mitochondrial function in stem cells with implications for stem cell self-renewal, cardiomyocyte regeneration, and neural stem/progenitor cell survival.</p>
</abstract>
<abstract abstract-type="graphical" id="abs0015">
<title>Graphical abstract</title>
<fig id="undfig1" position="anchor">
<graphic xlink:href="fx1"></graphic>
</fig>
</abstract>
<abstract abstract-type="author-highlights" id="abs0020">
<title>Highlights</title>
<p>
<list list-type="simple">
<list-item id="u0010">
<label>•</label>
<p>Nrf2 activity defends against mitochondrial toxins.</p>
</list-item>
<list-item id="u0015">
<label>•</label>
<p>The function of Nrf2 is suppressed in mitochondria-related disorders.</p>
</list-item>
<list-item id="u0020">
<label>•</label>
<p>Nrf2 deficiency leads to impaired mitochondrial fatty acid oxidation, respiration and ATP production.</p>
</list-item>
<list-item id="u0025">
<label>•</label>
<p>Small molecule activators of Nrf2 support mitochondrial integrity.</p>
</list-item>
<list-item id="u0030">
<label>•</label>
<p>Nrf2 affects mitochondrial function in stem cells.</p>
</list-item>
</list>
</p>
</abstract>
<kwd-group id="kwrds0010">
<title>Keywords</title>
<kwd>Glucoraphanin</kwd>
<kwd>Keap1</kwd>
<kwd>Mitohormesis</kwd>
<kwd>Mitophagy</kwd>
<kwd>Neurodegenerative disease</kwd>
<kwd>Nrf</kwd>
<kwd>PMI</kwd>
<kwd>RTA-408</kwd>
<kwd>Stem cells</kwd>
<kwd>Sulforaphane</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1">
<label>1</label>
<title>Introduction</title>
<p>The mitochondria are known as the powerhouse of the cell. The process of providing the cell with the bulk of its energy is intimately linked to the production of reactive oxygen species (ROS) during oxidative phosphorylation. In most cells, the mitochondria and NADPH oxidase are the main sources of ROS. Our understanding of the role of ROS within the cell is becoming increasingly complex. The traditional view of ROS simply being a harmful by-product of respiration is giving way to a more intricate picture where the role of ROS as an important signaling molecule is emerging <xref ref-type="bibr" rid="bib1">1</xref>, <xref ref-type="bibr" rid="bib2">2</xref>. It is however becoming evident that an imbalance in the generation of ROS is a common feature in several disease states, ranging from neurodegeneration and diabetes to cardiovascular disease and cancer <xref ref-type="bibr" rid="bib3">[3]</xref>.</p>
<p>As the master regulator of the cellular redox homeostasis, the cap ‘n’ collar basic leucine zipper (CNC-bZip) transcription factor, nuclear factor erythroid 2 p45-related factor 2 (Nrf2) is well equipped to counterbalance the mitochondrial ROS production and is critical for maintaining the redox balance in the cell <xref ref-type="bibr" rid="bib4">[4]</xref>. Following exposure to oxidants or electrophiles, Nrf2 accumulates in the nucleus. There, it binds to antioxidant response elements (ARE) in the upstream regulatory regions of genes encoding detoxification and antioxidant enzymes, leading to their enhanced transcription <xref ref-type="bibr" rid="bib4">4</xref>, <xref ref-type="bibr" rid="bib5">5</xref>, <xref ref-type="bibr" rid="bib6">6</xref>. Work from our laboratories and the laboratories of other investigators, has shown that the status of Nrf2 activity affects mitochondrial function, and this has been reviewed <xref ref-type="bibr" rid="bib7">7</xref>, <xref ref-type="bibr" rid="bib8">∗8</xref>, <xref ref-type="bibr" rid="bib9">9</xref>, <xref ref-type="bibr" rid="bib10">10</xref>. The current <italic>opinion article</italic> briefly summarizes the available experimental evidence and provides an update of the most recent findings in this area.</p>
</sec>
<sec id="sec2">
<label>2</label>
<title>Nrf2 regulation</title>
<p>Under basal conditions, Nrf2 is rapidly turned over, and the function of Nrf2 is primarily regulated by controlling the protein levels of the transcription factor through ubiquitination and proteasomal degradation. There are three known ubiquitin ligase systems that are responsible for Nrf2 degradation (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The first discovered and most studied is the Kelch-like ECH-associated protein 1 (Keap1)–Cullin3 (Cul3)/Rbx1 <xref ref-type="bibr" rid="bib11">11</xref>, <xref ref-type="bibr" rid="bib12">12</xref>, <xref ref-type="bibr" rid="bib13">13</xref>. As a negative regulator of Nrf2 <xref ref-type="bibr" rid="bib14">[14]</xref>, Keap1 serves as a substrate adaptor protein for the ubiquitin ligase Cul3/Rbx1. Keap1 binds Nrf2 in the cytoplasm and targets the transcription factor for ubiquitination and proteasomal degradation, maintaining Nrf2 at a low steady state level. Oxidants and electrophiles react with cysteine sensors within Keap1 <xref ref-type="bibr" rid="bib15">15</xref>, <xref ref-type="bibr" rid="bib16">16</xref>, <xref ref-type="bibr" rid="bib17">17</xref>, causing a conformational change <xref ref-type="bibr" rid="bib18">18</xref>, <xref ref-type="bibr" rid="bib19">∗19</xref> and the inability of Keap1 to target Nrf2 for degradation <xref ref-type="bibr" rid="bib20">[20]</xref>. This allows free Nrf2 to accumulate and translocate to the nucleus where it binds to a small Maf protein, activating the expression of its target genes <xref ref-type="bibr" rid="bib21">21</xref>, <xref ref-type="bibr" rid="bib22">∗∗22</xref>. Nrf2 is also subject to degradation following phosphorylation by glycogen synthase kinase 3 (GSK3) via β-transducin repeats-containing protein (β-TrCP)-Cul1-based ubiquitin ligase <xref ref-type="bibr" rid="bib23">∗23</xref>, <xref ref-type="bibr" rid="bib24">24</xref>. The most recently described ubiquitin-dependent system involved in Nrf2 degradation is the E3 ubiquitin ligase synoviolin (Hrd1), which resides in the endoplasmic reticulum <xref ref-type="bibr" rid="bib25">[25]</xref>.</p>
<p>Besides regulation of Nrf2 through its degradation, the function of the transcription factor is also controlled through the spatial distribution of both Nrf2 and Keap1. There are three pools of Nrf2 within the cell. In addition to the predominant cytoplasmic pool, there is a nuclear pool of Nrf2, the redistribution of which is controlled in part by Keap1-mediated degradation and by Nrf2 nuclear import signals and mediators <xref ref-type="bibr" rid="bib26">[26]</xref>. Nrf2 and Keap1 have also been detected at the outer mitochondrial membrane, tethered to the mitochondrial phosphatase phosphoglycerate mutase family member PGAM5 <xref ref-type="bibr" rid="bib27">[27]</xref>. The three pools of Nrf2 are highly dynamic and subjected to a further fine-tuned regulation. Thus, it has been reported that the ubiquitin-conjugating enzyme UBE2E3 and its nuclear import receptor importin 11 regulate Nrf2 distribution and activity, by restricting the transcription factor from partitioning to the mitochondria and limiting its repression by nuclear Keap1 <xref ref-type="bibr" rid="bib28">[28]</xref>.</p>
</sec>
<sec id="sec3">
<label>3</label>
<title>Nrf2 and the cellular redox homeostasis</title>
<p>Since its discovery in the mid-1990s <xref ref-type="bibr" rid="bib22">∗∗22</xref>, <xref ref-type="bibr" rid="bib29">∗29</xref>, Nrf2 has been extensively studied. The number of publications on Nrf2 has exceeded 7000, and continues to increase exponentially (<ext-link ext-link-type="uri" id="intref0010" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/?term=nrf2">http://www.ncbi.nlm.nih.gov/pubmed/?term=nrf2</ext-link>). Nrf2 has been associated with cytoprotective functions in animal models of a range of human disease conditions, and has been implicated in the regulation of over 600 target genes <xref ref-type="bibr" rid="bib30">[30]</xref>. Nrf2 targets include antioxidant enzymes, proteins involved in xenobiotic metabolism and clearance, protection against heavy metal toxicity, inhibition of inflammation, repair and removal of damaged proteins, as well as other transcription and growth factors <xref ref-type="bibr" rid="bib31">[31]</xref>. Nrf2 regulates the expression of γ-glutamyl cysteine ligase catalytic (GCLC) and modulatory (GCLM) subunits, glutathione reductase (GR) <xref ref-type="bibr" rid="bib21">21</xref>, <xref ref-type="bibr" rid="bib30">30</xref>, <xref ref-type="bibr" rid="bib32">32</xref>, <xref ref-type="bibr" rid="bib33">33</xref>, <xref ref-type="bibr" rid="bib34">34</xref>, <xref ref-type="bibr" rid="bib35">35</xref>, as well as the four enzymes [i.e. malic enzyme 1 (ME1), isocitrate dehydrogenase 1 (IDH1), glucose-6-phosphate dehydrogenase (G6PD), and 6-phosphogluconate dehydrogenase (6PGD)] that are responsible for the generation of NADPH <xref ref-type="bibr" rid="bib36">36</xref>, <xref ref-type="bibr" rid="bib37">37</xref>, <xref ref-type="bibr" rid="bib38">∗∗38</xref>, <xref ref-type="bibr" rid="bib39">39</xref>, <xref ref-type="bibr" rid="bib40">∗40</xref>, all of which are involved in the biosynthesis and maintenance of reduced glutathione (GSH). In turn, GSH, the principal small molecule antioxidant in the mammalian cell, counterbalances the production of ROS. In more recent years, it has emerged that one of the important functions of Nrf2 is to modulate mitochondrial function, as part of its role as a master regulator of cytoprotective gene expression and the cellular redox homeostasis (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The evidence for this is two fold. First, it has been shown that the Nrf2 pathway is upregulated and is involved in protection against mitochondrial toxins. Early work noted that increased Nrf2 activity enhanced resistance to mitochondrial toxins such as the complex I inhibitor rotenone or the complex II inhibitor 3-nitropropionic acid <italic>in vitro</italic> and <italic>in vivo</italic>
<xref ref-type="bibr" rid="bib41">41</xref>, <xref ref-type="bibr" rid="bib42">42</xref>, <xref ref-type="bibr" rid="bib43">∗43</xref>. Second, Nrf2 function has been reported to be impaired in mitochondria-related disorders, whereas Nrf2 activation has beneficial effects. For example, the Nrf2 pathway is suppressed in Parkinson's disease patient derived olfactory neurosphere cells <xref ref-type="bibr" rid="bib44">[44]</xref>, and Nrf2 activation restores the glutathione levels in these cells <xref ref-type="bibr" rid="bib45">[45]</xref>. This Nrf2 suppression is especially prominent in Friedrich's ataxia where Nrf2 activation upon oxidative stress was found to be blocked in patient fibroblasts <xref ref-type="bibr" rid="bib46">[46]</xref>.</p>
</sec>
<sec id="sec4">
<label>4</label>
<title>Nrf2 and mitochondrial homeostasis</title>
<p>In 2008, Lo and colleagues reported that Keap1 associates with PGAM5, establishing a physical link to mitochondria <xref ref-type="bibr" rid="bib27">[27]</xref>. That same year, an association between Nrf2 and mitochondrial biogenesis was found in cardiomyocytes, where Nrf2 stimulates the biogenesis program through activation of nuclear respiratory factor-1 (NRF-1) <xref ref-type="bibr" rid="bib47">[47]</xref>. This has since been confirmed in <italic>in vivo</italic> studies <xref ref-type="bibr" rid="bib48">[48]</xref>. What we have been interested in establishing is a more direct involvement of Nrf2 in modulating mitochondrial function (recently reviewed in <xref ref-type="bibr" rid="bib7">7</xref>, <xref ref-type="bibr" rid="bib8">∗8</xref>, <xref ref-type="bibr" rid="bib10">10</xref>). We showed that respiration and ATP levels are decreased in cells and mitochondria isolated from Nrf2-knockout (Nrf2-KO) mice, while they are increased in their Keap1-knockout (Keap1-KO) and Keap1-knockdown (Keap1-KD) counterparts <xref ref-type="bibr" rid="bib49">∗∗49</xref>, <xref ref-type="bibr" rid="bib50">50</xref>. Similarly, mitochondrial fatty acid oxidation is impaired in cells and mitochondria isolated from Nrf2-KO mice <xref ref-type="bibr" rid="bib51">[51]</xref>. This could potentially be the reason for the higher accumulation of triglycerides in the liver upon fasting in these mice <xref ref-type="bibr" rid="bib52">[52]</xref>. As the activities of the respiratory enzymes are not impaired <xref ref-type="bibr" rid="bib49">[49]</xref>, the decrease in respiration and ATP levels under conditions of Nrf2 deficiency argue that the main limitation is substrate availability.</p>
<p>Mitochondrial integrity is key to overall mitochondrial functionality. Mitophagy has emerged as a way to maintain the organelle integrity, by selectively removing damaged mitochondria <xref ref-type="bibr" rid="bib53">[53]</xref>. One of the critical players involved in this process is the autophagic adaptor protein sequestosome-1 (SQSTM1/p62) <xref ref-type="bibr" rid="bib54">[54]</xref>. p62 interacts with the Nrf2-binding site on Keap1, competing with Nrf2 for binding <xref ref-type="bibr" rid="bib55">∗55</xref>, <xref ref-type="bibr" rid="bib56">∗56</xref>. This interaction is further enhanced by phosphorylation <xref ref-type="bibr" rid="bib57">∗57</xref>, <xref ref-type="bibr" rid="bib58">58</xref>. Therefore, increased free p62 levels activate the Nrf2 pathway. p62 is also an Nrf2-target gene, thus creating a positive regulatory loop <xref ref-type="bibr" rid="bib55">∗55</xref>, <xref ref-type="bibr" rid="bib56">∗56</xref>. An Nrf2-dependent small-molecule mitophagy inducer (p62-mediated mitophagy inducer – PMI) (<xref ref-type="fig" rid="fig3">Figure 3</xref>) was recently discovered. PMI directly disrupts the Nrf2-Keap1 interaction <xref ref-type="bibr" rid="bib59">[59]</xref> and induces mitophagy independently of dissipation of the mitochondrial membrane potential and the mitochondrial serine/threonine-protein kinase PTEN-induced kinase 1 (PINK1)/Parkin pathway <xref ref-type="bibr" rid="bib60">[60]</xref>.</p>
<p>When mitochondrial integrity is lost beyond repair, the mitochondria can undergo permeability transition to induce cell death <xref ref-type="bibr" rid="bib61">[61]</xref>. Induction of Nrf2 using the isothiocyanate sulforaphane (<xref ref-type="fig" rid="fig3">Figure 3</xref>) <xref ref-type="bibr" rid="bib62">∗∗62</xref>, <xref ref-type="bibr" rid="bib63">63</xref> confers resistance to redox-regulated permeability transition <xref ref-type="bibr" rid="bib64">[64]</xref>, suggesting a further role for the Nrf2 pathway in maintaining mitochondrial integrity.</p>
</sec>
<sec id="sec5">
<label>5</label>
<title>Nrf2, mitochondrial function and neurological conditions</title>
<p>Neurodegenerative disorders are commonly characterized by oxidative stress, mitochondrial dysfunction and protein misfolding, making them ideal targets for Nrf2 activator mediated therapy (reviewed in <xref ref-type="bibr" rid="bib10">10</xref>, <xref ref-type="bibr" rid="bib65">65</xref>, <xref ref-type="bibr" rid="bib66">66</xref>). Nrf2 activation has long been shown to be cytoprotective in both toxicological as well as genetic models of neurodegeneration <italic>in vitro</italic> and <italic>in vivo</italic>
<xref ref-type="bibr" rid="bib67">∗67</xref>, <xref ref-type="bibr" rid="bib68">68</xref>, <xref ref-type="bibr" rid="bib69">∗69</xref>, <xref ref-type="bibr" rid="bib70">∗70</xref>, <xref ref-type="bibr" rid="bib71">71</xref>, <xref ref-type="bibr" rid="bib72">∗72</xref>, <xref ref-type="bibr" rid="bib73">73</xref>, <xref ref-type="bibr" rid="bib74">74</xref>, <xref ref-type="bibr" rid="bib75">75</xref>, <xref ref-type="bibr" rid="bib76">∗∗76</xref>. More recently, we have reported that treatment with the Nrf2 inducers RTA-408, a synthetic cyanoenone triterpenoid, or with the naturally occurring isothiocyanate sulforaphane (<xref ref-type="fig" rid="fig3">Figure 3</xref>) restored the mitochondrial membrane potential and protected against dopamine toxicity in primary co-cultures of midbrain neurons and astrocytes isolated from PINK1-KO mice, a model of hereditary early-onset Parkinson's disease <xref ref-type="bibr" rid="bib8">[8]</xref>. A wide variety of small molecule activators of the Nrf2 pathway have been established and tested in both <italic>in vitro</italic> and <italic>in vivo</italic> models of neurodegenerative diseases, including multiple sclerosis, Parkinson's, Huntington's and Alzheimer's disease (recently reviewed in <xref ref-type="bibr" rid="bib77">[77]</xref>), showing great promise as potential therapeutic agents. Sulforaphane has shown protective effects in a number of rodent models of neurological conditions (<xref ref-type="table" rid="tbl1">Table 1</xref>). Several Nrf2 activators are undergoing clinical trials; one of them, BG-12 (Tecfidera), has already entered clinical practice. BG-12 is an oral formulation of the Nrf2 inducer dimethyl fumarate (<xref ref-type="fig" rid="fig3">Figure 3</xref>), which is being used for the treatment of relapsing – remitting multiple sclerosis in humans <xref ref-type="bibr" rid="bib78">78</xref>, <xref ref-type="bibr" rid="bib79">79</xref>. Currently, the Nrf2 activator RTA-408 (<xref ref-type="fig" rid="fig3">Figure 3</xref>) is being tested for treatment of Friedrich's ataxia (<ext-link ext-link-type="uri" id="intref0015" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link>, <ext-link ext-link-type="uri" id="intref0020" xlink:href="ctgov:NCT02255435">NCT02255435</ext-link>). The potential of GSK3 inhibitors (Tideglusib) in Alzheimer's disease was explored in a small Phase II clinical trial. Although in this trial no overall statistically significant clinical benefit for the drug was found, it was noted that there was a significant decrease in the levels of β-secretase 1 (BACE1) in cerebrospinal fluid in a subgroup of patients <xref ref-type="bibr" rid="bib80">[80]</xref>.</p>
<p>A recent study reported the ability of sulforaphane to improve social interaction and verbal communication, reversing abnormal behavior in young men with autism spectrum disorder <xref ref-type="bibr" rid="bib81">[81]</xref>. Interestingly, granulocytes of children with autism exhibit defects in oxidative phosphorylation and reduced gene expression of Nrf2 <xref ref-type="bibr" rid="bib82">[82]</xref>. In healthy human subjects, metabolic profiling after a dietary intervention with broccoli as a source of glucoraphanin, the precursor of sulforaphane, has indicated enhanced integration of fatty acid oxidation with the activity of the TCA cycle <xref ref-type="bibr" rid="bib83">[83]</xref>. Taken together, these studies suggest that sulforaphane-mediated Nrf2 activation may lead to improved mitochondrial function and thus contribute to reversal of the behavioral abnormalities in autism.</p>
</sec>
<sec id="sec6">
<label>6</label>
<title>Nrf2 and mitohormesis</title>
<p>An interesting concept that has grown in popularity is the involvement of Nrf2 signaling in hormesis. Hormesis refers to the exposure to low levels of stress such as ROS, which will prime the cell or organism to better handle future insults <xref ref-type="bibr" rid="bib84">[84]</xref>. Mitohormesis more specifically suggests that the mitochondria might be essential for this process <xref ref-type="bibr" rid="bib85">[85]</xref>. Nrf2 has been suggested multiple times to have hormetic potential <xref ref-type="bibr" rid="bib84">84</xref>, <xref ref-type="bibr" rid="bib86">86</xref>, <xref ref-type="bibr" rid="bib87">87</xref>. This has been extensively discussed in the context of nutritional antioxidants and dietary restriction <xref ref-type="bibr" rid="bib88">[88]</xref>, where it has been shown that Nrf2 is in part responsible for the beneficial effects of dietary restriction through activation of the phase 2 response. SKN-1, the Nrf ortholog in the nematode <italic>Caenorhabditis elegans</italic>, has been shown to be a longevity factor <xref ref-type="bibr" rid="bib89">89</xref>, <xref ref-type="bibr" rid="bib90">90</xref>. SKN-1 activation reduces the accumulation of ROS and increases proteasome activity, stress resistance, and lifespan <xref ref-type="bibr" rid="bib89">89</xref>, <xref ref-type="bibr" rid="bib91">91</xref>. The exact mechanism is not fully understood, but SKN-1 is responsible for mitochondria-associated redox signaling <xref ref-type="bibr" rid="bib90">[90]</xref>, and for coupling proline catabolism with fatty acid oxidation during limited nutrient availability <xref ref-type="bibr" rid="bib92">[92]</xref>.</p>
<p>Most recently, Nrf2 activation was linked to lithium-mediated lifespan extension in <italic>Drosophila melanogaster</italic>
<xref ref-type="bibr" rid="bib93">[93]</xref>. Lithium inhibits GSK3, and this inhibition stabilizes and activates Nrf2 (<xref ref-type="fig" rid="fig1">Figure 1</xref>), thus extending the lifespan of the flies, specifically at low doses. As with any hormetic response, excessive levels of the toxin, and even excessive Nrf2 activation, has detrimental consequences and decreases lifespan. This is in line with the phenotype of the Keap1-KO mice, which die postnatally from hyperkeratosis of the esophagus due to constitutive Nrf2 activation <xref ref-type="bibr" rid="bib94">[94]</xref>, and with the reduced longevity due to prolonged Nrf2 overexpression in transgenic <italic>Drosophila melanogaster</italic>
<xref ref-type="bibr" rid="bib95">[95]</xref>.</p>
</sec>
<sec id="sec7">
<label>7</label>
<title>Emerging role of Nrf2 in mitochondrial function in stem cells</title>
<p>Although not an entirely novel concept, 2016 has seen a surge in high impact publications that have explored the relationship between Nrf2 and mitochondrial function in the context of stem cell biology. Decreased levels of Nrf2 were shown to correlate with the decrease in regenerative capacity of subventricular zone neural stem/progenitor cells (NSPCs) in the rat <xref ref-type="bibr" rid="bib96">[96]</xref>. Intriguing work by Khacho and colleagues <xref ref-type="bibr" rid="bib97">[97]</xref> suggests that dynamic changes in the mitochondrial network during neural stem cell development induce ROS-dependent Nrf2-mediated transcriptional activation of cell differentiation. The metabolic reprogramming from oxidative phosphorylation to glycolytic energy production that takes place during the induction of pluripotent stem cells differentiation is also dependent on ROS-mediated Nrf2 activation <xref ref-type="bibr" rid="bib98">∗∗98</xref>, <xref ref-type="bibr" rid="bib99">99</xref>. In the heart, Nrf2 is necessary for neonatal myocardial regeneration after apex resection by activating paired-like homeodomain transcription factor 2 (Pitx2), which then activates antioxidant genes as well as components of the electron transport chain <xref ref-type="bibr" rid="bib100">[100]</xref>.</p>
<p>The age-related decline in the regenerative function of neural stem/progenitor cells has been causally linked to decreased expression of Nrf2 <xref ref-type="bibr" rid="bib98">[98]</xref>. A recent report found that Nrf2 activity is impaired in the premature aging disorder Hutchinson-Gilford progeria syndrome (HGPS) due to progerin sequestration of Nrf2, leading to subnuclear mislocalization of the transcription factor <xref ref-type="bibr" rid="bib101">[101]</xref>. Reactivation of the Nrf2 pathway reverses the cellular phenotype, including key phenotypes of the disease, such as reduced viability of mesenchymal stem cells <xref ref-type="bibr" rid="bib101">[101]</xref> and impaired autophagy <xref ref-type="bibr" rid="bib102">[102]</xref>, while inactivation of the pathway recapitulates some of the aging phenotypes in HGPS. Together, these studies show that Nrf2 is an important player in stem cell biology and cell senescence, and implicate its role in mitochondrial function as a possible mechanistic link.</p>
</sec>
<sec id="sec8">
<label>8</label>
<title>Concluding remarks and future directions</title>
<p>Work from a number of independent laboratories has convincingly demonstrated that the status of Nrf2 activity affects many aspects of mitochondrial physiology, including mitochondrial biogenesis, fatty acid oxidation, respiration, ATP production, redox homeostasis, as well as the structural integrity and dynamics of this essential organelle. In parallel to recognizing that many human pathological conditions and aging are associated with mitochondrial dysfunction, it is becoming increasingly apparent that this often coincides with suppressed Nrf2 signaling. Most excitingly, the ability to reactivate Nrf2 by pharmacological agents is a promising strategy for the prevention or treatment of chronic degenerative diseases and for achieving healthy aging. Importantly, pharmacological Nrf2 activators include phytochemicals (e.g. sulforaphane) that are present in plants, such as cruciferous vegetables, which have been an important part of the human diet for centuries, and are largely responsible for the health-promoting effects of plant-rich diets. As both insufficient as well as persistently high Nrf2 activity can have detrimental consequences, it will be critical to understand what is the appropriate “dose” of Nrf2 activity that would restore the balance and correct the pathological phenotypes.</p>
</sec>
</body>
<back>
<ref-list id="cebib0010">
<title>References</title>
<ref id="bib1">
<label>1</label>
<element-citation id="sref1" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmström</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Finkel</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Cellular mechanisms and physiological consequences of redox-dependent signalling</article-title>
<source/>Nat Rev Mol Cell Biol
          <volume>15</volume>
<year>2014</year>
<fpage>411</fpage>
<lpage>421</lpage>
<pub-id pub-id-type="pmid">24854789</pub-id>
</element-citation>
</ref>
<ref id="bib2">
<label>2</label>
<element-citation id="sref2" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nickel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kohlhaas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Maack</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Mitochondrial reactive oxygen species production and elimination</article-title>
<source/>J Mol Cell Cardiol
          <volume>73</volume>
<year>2014</year>
<fpage>26</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="pmid">24657720</pub-id>
</element-citation>
</ref>
<ref id="bib3">
<label>3</label>
<element-citation id="sref3" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pham-Huy</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Pham-Huy</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Free radicals, antioxidants in disease and health</article-title>
<source/>Int J Biomed Sci
          <volume>4</volume>
<year>2008</year>
<fpage>89</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="pmid">23675073</pub-id>
</element-citation>
</ref>
<ref id="bib4">
<label>4</label>
<element-citation id="sref4" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayes</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Dinkova-Kostova</surname>
<given-names>A.T.</given-names>
</name>
</person-group>
<article-title>The Nrf2 regulatory network provides an interface between redox and intermediary metabolism</article-title>
<source/>Trends Biochem Sci
          <volume>39</volume>
<year>2014</year>
<fpage>199</fpage>
<lpage>218</lpage>
<pub-id pub-id-type="pmid">24647116</pub-id>
</element-citation>
</ref>
<ref id="bib5">
<label>5</label>
<element-citation id="sref5" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Motohashi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Toward clinical application of the Keap1–Nrf2 pathway</article-title>
<source/>Trends Pharmacol Sci
          <volume>34</volume>
<year>2013</year>
<fpage>340</fpage>
<lpage>346</lpage>
<pub-id pub-id-type="pmid">23664668</pub-id>
</element-citation>
</ref>
<ref id="bib6">
<label>6</label>
<element-citation id="sref6" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kensler</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Wakabayashi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Biswal</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Cell survival responses to environmental stresses via the Keap1–Nrf2–ARE pathway</article-title>
<source/>Annu Rev Pharmacol Toxicol
          <volume>47</volume>
<year>2007</year>
<fpage>89</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="pmid">16968214</pub-id>
</element-citation>
</ref>
<ref id="bib7">
<label>7</label>
<element-citation id="sref7" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinkova-Kostova</surname>
<given-names>A.T.</given-names>
</name>
<name>
<surname>Abramov</surname>
<given-names>A.Y.</given-names>
</name>
</person-group>
<article-title>The emerging role of Nrf2 in mitochondrial function</article-title>
<source/>Free Radic Biol Med
          <volume>88</volume>
<year>2015</year>
<fpage>179</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="pmid">25975984</pub-id>
</element-citation>
</ref>
<ref id="bib8">
<element-citation id="sref8" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinkova-Kostova</surname>
<given-names>A.T.</given-names>
</name>
<name>
<surname>Baird</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Holmström</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Abramov</surname>
<given-names>A.Y.</given-names>
</name>
</person-group>
<article-title>The spatiotemporal regulation of the Keap1–Nrf2 pathway and its importance in cellular bioenergetics</article-title>
<source/>Biochem Soc Trans
          <volume>43</volume>
<year>2015</year>
<fpage>602</fpage>
<lpage>610</lpage>
<pub-id pub-id-type="pmid">26551700</pub-id>
</element-citation>
<note>
<p>Restoration of the mitochondrial membrane potential by pharmacological Nrf2 activation in PINK1-deficient primary neuronal cultures.</p>
</note>
</ref>
<ref id="bib9">
<label>9</label>
<element-citation id="sref9" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itoh</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Matsumiya</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tanji</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ozaki</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Emerging functional cross-talk between the Keap1–Nrf2 system and mitochondria</article-title>
<source/>J Clin Biochem Nutr
          <volume>56</volume>
<year>2015</year>
<fpage>91</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="pmid">25759513</pub-id>
</element-citation>
</ref>
<ref id="bib10">
<label>10</label>
<element-citation id="sref10" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Esteras</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Dinkova-Kostova</surname>
<given-names>A.T.</given-names>
</name>
<name>
<surname>Abramov</surname>
<given-names>A.Y.</given-names>
</name>
</person-group>
<article-title>Nrf2 activation in the treatment of neurodegenerative diseases: a focus on its role in mitochondrial bioenergetics and function</article-title>
<source/>Biol Chem
          <volume>397</volume>
<year>2016</year>
<fpage>383</fpage>
<lpage>400</lpage>
<pub-id pub-id-type="pmid">26812787</pub-id>
</element-citation>
</ref>
<ref id="bib11">
<label>11</label>
<element-citation id="sref11" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>D.D.</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Cross</surname>
<given-names>J.V.</given-names>
</name>
<name>
<surname>Templeton</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Hannink</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex</article-title>
<source/>Mol Cell Biol
          <volume>24</volume>
<year>2004</year>
<fpage>10941</fpage>
<lpage>10953</lpage>
<pub-id pub-id-type="pmid">15572695</pub-id>
</element-citation>
</ref>
<ref id="bib12">
<label>12</label>
<element-citation id="sref12" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kobayashi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Okawa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ohtsuji</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zenke</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chiba</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2</article-title>
<source/>Mol Cell Biol
          <volume>24</volume>
<year>2004</year>
<fpage>7130</fpage>
<lpage>7139</lpage>
<pub-id pub-id-type="pmid">15282312</pub-id>
</element-citation>
</ref>
<ref id="bib13">
<label>13</label>
<element-citation id="sref13" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cullinan</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Gordan</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Harper</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Diehl</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>The Keap1–BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase</article-title>
<source/>Mol Cell Biol
          <volume>24</volume>
<year>2004</year>
<fpage>8477</fpage>
<lpage>8486</lpage>
<pub-id pub-id-type="pmid">15367669</pub-id>
</element-citation>
</ref>
<ref id="bib14">
<element-citation id="sref14" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itoh</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wakabayashi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ishii</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Igarashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain</article-title>
<source/>Genes Dev
          <volume>13</volume>
<year>1999</year>
<fpage>76</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="pmid">9887101</pub-id>
</element-citation>
<note>
<p>Discovery of Keap1.</p>
</note>
</ref>
<ref id="bib15">
<label>15</label>
<element-citation id="sref15" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinkova-Kostova</surname>
<given-names>A.T.</given-names>
</name>
<name>
<surname>Holtzclaw</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>R.N.</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wakabayashi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants</article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>99</volume>
<year>2002</year>
<fpage>11908</fpage>
<lpage>11913</lpage>
<pub-id pub-id-type="pmid">12193649</pub-id>
</element-citation>
</ref>
<ref id="bib16">
<label>16</label>
<element-citation id="sref16" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McMahon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lamont</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Beattie</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals</article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>107</volume>
<year>2010</year>
<fpage>18838</fpage>
<lpage>18843</lpage>
<pub-id pub-id-type="pmid">20956331</pub-id>
</element-citation>
</ref>
<ref id="bib17">
<label>17</label>
<element-citation id="sref17" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinkova-Kostova</surname>
<given-names>A.T.</given-names>
</name>
<name>
<surname>Liby</surname>
<given-names>K.T.</given-names>
</name>
<name>
<surname>Stephenson</surname>
<given-names>K.K.</given-names>
</name>
<name>
<surname>Holtzclaw</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress</article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>102</volume>
<year>2005</year>
<fpage>4584</fpage>
<lpage>4589</lpage>
<pub-id pub-id-type="pmid">15767573</pub-id>
</element-citation>
</ref>
<ref id="bib18">
<label>18</label>
<element-citation id="sref18" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinkova-Kostova</surname>
<given-names>A.T.</given-names>
</name>
<name>
<surname>Holtzclaw</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>Wakabayashi</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Keap1, the sensor for electrophiles and oxidants that regulates the phase 2 response, is a zinc metalloprotein</article-title>
<source/>Biochemistry
          <volume>44</volume>
<year>2005</year>
<fpage>6889</fpage>
<lpage>6899</lpage>
<pub-id pub-id-type="pmid">15865434</pub-id>
</element-citation>
</ref>
<ref id="bib19">
<element-citation id="sref19" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baird</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Llères</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Swift</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dinkova-Kostova</surname>
<given-names>A.T.</given-names>
</name>
</person-group>
<article-title>Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1–Nrf2 protein complex</article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>110</volume>
<year>2013</year>
<fpage>15259</fpage>
<lpage>15264</lpage>
<pub-id pub-id-type="pmid">23986495</pub-id>
</element-citation>
<note>
<p>Conceptually new model of Keap1-mediated regulation of Nrf2.</p>
</note>
</ref>
<ref id="bib20">
<label>20</label>
<element-citation id="sref20" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>D.D.</given-names>
</name>
<name>
<surname>Hannink</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress</article-title>
<source/>Mol Cell Biol
          <volume>23</volume>
<year>2003</year>
<fpage>8137</fpage>
<lpage>8151</lpage>
<pub-id pub-id-type="pmid">14585973</pub-id>
</element-citation>
</ref>
<ref id="bib21">
<label>21</label>
<element-citation id="sref21" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirotsu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Katsuoka</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Funayama</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nagashima</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nishida</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Nrf2–MafG heterodimers contribute globally to antioxidant and metabolic networks</article-title>
<source/>Nucleic Acids Res
          <volume>40</volume>
<year>2012</year>
<fpage>10228</fpage>
<lpage>10239</lpage>
<pub-id pub-id-type="pmid">22965115</pub-id>
</element-citation>
</ref>
<ref id="bib22">
<element-citation id="sref22" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itoh</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chiba</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ishii</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Igarashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Katoh</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements</article-title>
<source/>Biochem Biophys Res Commun
          <volume>236</volume>
<year>1997</year>
<fpage>313</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="pmid">9240432</pub-id>
</element-citation>
<note>
<p>Discovery of Nrf2 in the context of the environmantal stress response.</p>
</note>
</ref>
<ref id="bib23">
<element-citation id="sref23" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rada</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rojo</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Chowdhry</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Cuadrado</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>SCF/β-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner</article-title>
<source/>Mol Cell Biol
          <volume>31</volume>
<year>2011</year>
<fpage>1121</fpage>
<lpage>1133</lpage>
<pub-id pub-id-type="pmid">21245377</pub-id>
</element-citation>
<note>
<p>Keap1-independent GSK3-dependend Nrf2 degradation.</p>
</note>
</ref>
<ref id="bib24">
<label>24</label>
<element-citation id="sref24" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chowdhry</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sutherland</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cuadrado</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity</article-title>
<source/>Oncogene
          <volume>32</volume>
<year>2013</year>
<fpage>3765</fpage>
<lpage>3781</lpage>
<pub-id pub-id-type="pmid">22964642</pub-id>
</element-citation>
</ref>
<ref id="bib25">
<element-citation id="sref25" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yagishita</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nakajima</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis</article-title>
<source/>Genes Dev
          <volume>28</volume>
<year>2014</year>
<fpage>708</fpage>
<lpage>722</lpage>
<pub-id pub-id-type="pmid">24636985</pub-id>
</element-citation>
<note>
<p>Discovery of Hrd1-mediated Nrf2 degradation.</p>
</note>
</ref>
<ref id="bib26">
<label>26</label>
<element-citation id="sref26" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jain</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Jaiswal</surname>
<given-names>A.K.</given-names>
</name>
</person-group>
<article-title>Nuclear import and export signals in control of Nrf2</article-title>
<source/>J Biol Chem
          <volume>280</volume>
<year>2005</year>
<fpage>29158</fpage>
<lpage>29168</lpage>
<pub-id pub-id-type="pmid">15901726</pub-id>
</element-citation>
</ref>
<ref id="bib27">
<element-citation id="sref27" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Hannink</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>PGAM5 tethers a ternary complex containing Keap1 and Nrf2 to mitochondria</article-title>
<source/>Exp Cell Res
          <volume>314</volume>
<year>2008</year>
<fpage>1789</fpage>
<lpage>1803</lpage>
<pub-id pub-id-type="pmid">18387606</pub-id>
</element-citation>
<note>
<p>Discovery of the Keap1–Nrf2–PGAM5 tertiary complex.</p>
</note>
</ref>
<ref id="bib28">
<element-citation id="sref28" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plafker</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Plafker</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>The ubiquitin-conjugating enzyme UBE2E3 and its import receptor importin-11 regulate the localization and activity of the antioxidant transcription factor NRF2</article-title>
<source/>Mol Biol Cell
          <volume>26</volume>
<year>2015</year>
<fpage>327</fpage>
<lpage>338</lpage>
<pub-id pub-id-type="pmid">25378586</pub-id>
</element-citation>
<note>
<p>Nrf2 regulation by endogenous UBE2E3.</p>
</note>
</ref>
<ref id="bib29">
<element-citation id="sref29" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Asunis</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kan</surname>
<given-names>Y.W.</given-names>
</name>
</person-group>
<article-title>Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region</article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>91</volume>
<year>1994</year>
<fpage>9926</fpage>
<lpage>9930</lpage>
<pub-id pub-id-type="pmid">7937919</pub-id>
</element-citation>
<note>
<p>Discovery of Nrf2.</p>
</note>
</ref>
<ref id="bib30">
<label>30</label>
<element-citation id="sref30" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malhotra</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Portales-Casamar</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Arenillas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Happel</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis</article-title>
<source/>Nucleic Acids Res
          <volume>38</volume>
<year>2010</year>
<fpage>5718</fpage>
<lpage>5734</lpage>
<pub-id pub-id-type="pmid">20460467</pub-id>
</element-citation>
</ref>
<ref id="bib31">
<label>31</label>
<element-citation id="sref31" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baird</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dinkova-Kostova</surname>
<given-names>A.T.</given-names>
</name>
</person-group>
<article-title>The cytoprotective role of the Keap1–Nrf2 pathway</article-title>
<source/>Arch Toxicol
          <volume>85</volume>
<year>2011</year>
<fpage>241</fpage>
<lpage>272</lpage>
<pub-id pub-id-type="pmid">21365312</pub-id>
</element-citation>
</ref>
<ref id="bib32">
<label>32</label>
<element-citation id="sref32" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wild</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Moinova</surname>
<given-names>H.R.</given-names>
</name>
<name>
<surname>Mulcahy</surname>
<given-names>R.T.</given-names>
</name>
</person-group>
<article-title>Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2</article-title>
<source/>J Biol Chem
          <volume>274</volume>
<year>1999</year>
<fpage>33627</fpage>
<lpage>33636</lpage>
<pub-id pub-id-type="pmid">10559251</pub-id>
</element-citation>
</ref>
<ref id="bib33">
<label>33</label>
<element-citation id="sref33" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wild</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Mulcahy</surname>
<given-names>R.T.</given-names>
</name>
</person-group>
<article-title>Regulation of gamma-glutamylcysteine synthetase subunit gene expression: insights into transcriptional control of antioxidant defenses</article-title>
<source/>Free Radic Res
          <volume>32</volume>
<year>2000</year>
<fpage>281</fpage>
<lpage>301</lpage>
<pub-id pub-id-type="pmid">10741850</pub-id>
</element-citation>
</ref>
<ref id="bib34">
<label>34</label>
<element-citation id="sref34" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacLeod</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Plummer</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Higgins</surname>
<given-names>L.G.</given-names>
</name>
<name>
<surname>Penning</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Igarashi</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1–NRF2 pathway, and not the BACH1–NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds</article-title>
<source/>Carcinogenesis
          <volume>30</volume>
<year>2009</year>
<fpage>1571</fpage>
<lpage>1580</lpage>
<pub-id pub-id-type="pmid">19608619</pub-id>
</element-citation>
</ref>
<ref id="bib35">
<label>35</label>
<element-citation id="sref35" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agyeman</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Chaerkady</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>N.E.</given-names>
</name>
<name>
<surname>Visvanathan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pandey</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles</article-title>
<source/>Breast Cancer Res Treat
          <volume>132</volume>
<year>2012</year>
<fpage>175</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="pmid">21597922</pub-id>
</element-citation>
</ref>
<ref id="bib36">
<label>36</label>
<element-citation id="sref36" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Calkins</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kan</surname>
<given-names>Y.W.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis</article-title>
<source/>J Biol Chem
          <volume>278</volume>
<year>2003</year>
<fpage>12029</fpage>
<lpage>12038</lpage>
<pub-id pub-id-type="pmid">12556532</pub-id>
</element-citation>
</ref>
<ref id="bib37">
<label>37</label>
<element-citation id="sref37" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thimmulappa</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Mai</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Srisuma</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kensler</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Biswal</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray</article-title>
<source/>Cancer Res
          <volume>62</volume>
<year>2002</year>
<fpage>5196</fpage>
<lpage>5203</lpage>
<pub-id pub-id-type="pmid">12234984</pub-id>
</element-citation>
</ref>
<ref id="bib38">
<element-citation id="sref38" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitsuishi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Taguchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kawatani</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shibata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nukiwa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Aburatani</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming</article-title>
<source/>Cancer Cell
          <volume>22</volume>
<year>2012</year>
<fpage>66</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="pmid">22789539</pub-id>
</element-citation>
<note>
<p>Nrf2 redirects glucose towards the pentose phosphate pathway in rapidly proliferating cells.</p>
</note>
</ref>
<ref id="bib39">
<label>39</label>
<element-citation id="sref39" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Happel</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Manna</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Acquaah-Mensah</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Carrerero</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis</article-title>
<source/>J Clin Invest
          <volume>123</volume>
<year>2013</year>
<fpage>2921</fpage>
<lpage>2934</lpage>
<pub-id pub-id-type="pmid">23921124</pub-id>
</element-citation>
</ref>
<ref id="bib40">
<element-citation id="sref40" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Klaassen</surname>
<given-names>C.D.</given-names>
</name>
</person-group>
<article-title>Beneficial role of Nrf2 in regulating NADPH generation and consumption</article-title>
<source/>Toxicol Sci
          <volume>123</volume>
<year>2011</year>
<fpage>590</fpage>
<lpage>600</lpage>
<pub-id pub-id-type="pmid">21775727</pub-id>
</element-citation>
<note>
<p>The role of Nrf2 in NADPH generation and consumption.</p>
</note>
</ref>
<ref id="bib41">
<label>41</label>
<element-citation id="sref41" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Shih</surname>
<given-names>A.Y.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>T.H.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons</article-title>
<source/>J Biol Chem
          <volume>278</volume>
<year>2003</year>
<fpage>37948</fpage>
<lpage>37956</lpage>
<pub-id pub-id-type="pmid">12842875</pub-id>
</element-citation>
</ref>
<ref id="bib42">
<label>42</label>
<element-citation id="sref42" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shih</surname>
<given-names>A.Y.</given-names>
</name>
<name>
<surname>Imbeault</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Barakauskas</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Erb</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo</article-title>
<source/>J Biol Chem
          <volume>280</volume>
<year>2005</year>
<fpage>22925</fpage>
<lpage>22936</lpage>
<pub-id pub-id-type="pmid">15840590</pub-id>
</element-citation>
</ref>
<ref id="bib43">
<element-citation id="sref43" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calkins</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Jakel</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kan</surname>
<given-names>Y.W.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription</article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>102</volume>
<year>2005</year>
<fpage>244</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="pmid">15611470</pub-id>
</element-citation>
<note>
<p>Nrf2 protects against mitochondrial complex II inhibition.</p>
</note>
</ref>
<ref id="bib44">
<label>44</label>
<element-citation id="sref44" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matigian</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Abrahamsen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sutharsan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Vitale</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Nouwens</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Disease-specific, neurosphere-derived cells as models for brain disorders</article-title>
<source/>Dis Model Mech
          <volume>3</volume>
<year>2010</year>
<fpage>785</fpage>
<lpage>798</lpage>
<pub-id pub-id-type="pmid">20699480</pub-id>
</element-citation>
</ref>
<ref id="bib45">
<label>45</label>
<element-citation id="sref45" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cook</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Vitale</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Ravishankar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Matigian</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sutherland</surname>
<given-names>G.T.</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>NRF2 activation restores disease related metabolic deficiencies in olfactory neurosphere-derived cells from patients with sporadic Parkinson's disease</article-title>
<source/>PloS One
          <volume>6</volume>
<year>2011</year>
<fpage>e21907</fpage>
<pub-id pub-id-type="pmid">21747966</pub-id>
</element-citation>
</ref>
<ref id="bib46">
<element-citation id="sref46" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paupe</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Dassa</surname>
<given-names>E.P.</given-names>
</name>
<name>
<surname>Goncalves</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Auchere</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Lonn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Holmgren</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia</article-title>
<source/>PLoS One
          <volume>4</volume>
<year>2009</year>
<fpage>e4253</fpage>
<pub-id pub-id-type="pmid">19158945</pub-id>
</element-citation>
<note>
<p>Nrf2 signalling is impaired in Friedreich ataxia.</p>
</note>
</ref>
<ref id="bib47">
<element-citation id="sref47" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piantadosi</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Carraway</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Babiker</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Suliman</surname>
<given-names>H.B.</given-names>
</name>
</person-group>
<article-title>Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1</article-title>
<source/>Circ Res
          <volume>103</volume>
<year>2008</year>
<fpage>1232</fpage>
<lpage>1240</lpage>
<pub-id pub-id-type="pmid">18845810</pub-id>
</element-citation>
<note>
<p>Nrf2 as a regulator of mitochondrial biogenesis.</p>
</note>
</ref>
<ref id="bib48">
<label>48</label>
<element-citation id="sref48" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merry</surname>
<given-names>T.L.</given-names>
</name>
<name>
<surname>Ristow</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Nuclear factor erythroid-derived 2-like 2 (NFE2L2, Nrf2) mediates exercise-induced mitochondrial biogenesis and antioxidant response in mice</article-title>
<source/>J Physiol
          <volume>594</volume>
<year>2016</year>
<fpage>5195</fpage>
<lpage>5207</lpage>
<pub-id pub-id-type="pmid">27094017</pub-id>
</element-citation>
</ref>
<ref id="bib49">
<element-citation id="sref49" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmström</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Baird</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hargreaves</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Chalasani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Land</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration</article-title>
<source/>Biol Open
          <volume>2</volume>
<year>2013</year>
<fpage>761</fpage>
<lpage>770</lpage>
<pub-id pub-id-type="pmid">23951401</pub-id>
</element-citation>
<note>
<p>Nrf2 regulates mitochondrial function.</p>
</note>
</ref>
<ref id="bib50">
<label>50</label>
<element-citation id="sref50" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kovac</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Angelova</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Holmström</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dinkova-Kostova</surname>
<given-names>A.T.</given-names>
</name>
<name>
<surname>Abramov</surname>
<given-names>A.Y.</given-names>
</name>
</person-group>
<article-title>Nrf2 regulates ROS production by mitochondria and NADPH oxidase</article-title>
<source/>Biochim Biophys Acta
          <volume>1850</volume>
<year>2014</year>
<fpage>794</fpage>
<lpage>801</lpage>
<pub-id pub-id-type="pmid">25484314</pub-id>
</element-citation>
</ref>
<ref id="bib51">
<element-citation id="sref51" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ludtmann</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Angelova</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Abramov</surname>
<given-names>A.Y.</given-names>
</name>
<name>
<surname>Dinkova-Kostova</surname>
<given-names>A.T.</given-names>
</name>
</person-group>
<article-title>Nrf2 affects the efficiency of mitochondrial fatty acid oxidation</article-title>
<source/>Biochem J
          <volume>457</volume>
<year>2014</year>
<fpage>415</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="pmid">24206218</pub-id>
</element-citation>
<note>
<p>Nrf2 affects mitochondrial fatty acid oxidation.</p>
</note>
</ref>
<ref id="bib52">
<label>52</label>
<element-citation id="sref52" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.K.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>Klaassen</surname>
<given-names>C.D.</given-names>
</name>
</person-group>
<article-title>Genetic activation of Nrf2 protects against fasting-induced oxidative stress in livers of mice</article-title>
<source/>PLoS One
          <volume>8</volume>
<year>2013</year>
<fpage>e59122</fpage>
<pub-id pub-id-type="pmid">23527105</pub-id>
</element-citation>
</ref>
<ref id="bib53">
<label>53</label>
<element-citation id="sref53" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Youle</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Finkel</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>The mitochondrial basis of aging</article-title>
<source/>Mol Cell
          <volume>61</volume>
<year>2016</year>
<fpage>654</fpage>
<lpage>666</lpage>
<pub-id pub-id-type="pmid">26942670</pub-id>
</element-citation>
</ref>
<ref id="bib54">
<element-citation id="sref54" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geisler</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Holmström</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Skujat</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Fiesel</surname>
<given-names>F.C.</given-names>
</name>
<name>
<surname>Rothfuss</surname>
<given-names>O.C.</given-names>
</name>
<name>
<surname>Kahle</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1</article-title>
<source/>Nat Cell Biol
          <volume>12</volume>
<year>2010</year>
<fpage>119</fpage>
<lpage>131</lpage>
<pub-id pub-id-type="pmid">20098416</pub-id>
</element-citation>
<note>
<p>p62 dependence of PINK1/Parkin-mediated mitophagy.</p>
</note>
</ref>
<ref id="bib55">
<element-citation id="sref55" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Komatsu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kurokawa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Waguri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Taguchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ichimura</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1</article-title>
<source/>Nat Cell Biol
          <volume>12</volume>
<year>2010</year>
<fpage>213</fpage>
<lpage>223</lpage>
<pub-id pub-id-type="pmid">20173742</pub-id>
</element-citation>
<note>
<p>p62 activates Nrf2.</p>
</note>
</ref>
<ref id="bib56">
<element-citation id="sref56" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jain</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lamark</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sjottem</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>K.B.</given-names>
</name>
<name>
<surname>Awuh</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Overvatn</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription</article-title>
<source/>J Biol Chem
          <volume>285</volume>
<year>2010</year>
<fpage>22576</fpage>
<lpage>22591</lpage>
<pub-id pub-id-type="pmid">20452972</pub-id>
</element-citation>
<note>
<p>p62 and Nrf2 engage in a positive feedback regulatory loop.</p>
</note>
</ref>
<ref id="bib57">
<element-citation id="sref57" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ichimura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Waguri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sou</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Kageyama</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ishimura</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Phosphorylation of p62 activates the Keap1–Nrf2 pathway during selective autophagy</article-title>
<source/>Mol Cell
          <volume>51</volume>
<year>2013</year>
<fpage>618</fpage>
<lpage>631</lpage>
<pub-id pub-id-type="pmid">24011591</pub-id>
</element-citation>
<note>
<p>Phosphorylation of p62 increases its affinity to Keap1.</p>
</note>
</ref>
<ref id="bib58">
<label>58</label>
<element-citation id="sref58" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hancock</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Tsujita</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Naz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>El-Bakry</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Laoruchupong</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Peptide inhibitors of the Keap1–Nrf2 protein-protein interaction</article-title>
<source/>Free Radic Biol Med
          <volume>52</volume>
<year>2012</year>
<fpage>444</fpage>
<lpage>451</lpage>
<pub-id pub-id-type="pmid">22107959</pub-id>
</element-citation>
</ref>
<ref id="bib59">
<label>59</label>
<element-citation id="sref59" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertrand</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Schaap</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Baird</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Georgakopoulos</surname>
<given-names>N.D.</given-names>
</name>
<name>
<surname>Fowkes</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Thiollier</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Design, synthesis, and evaluation of triazole derivatives that induce Nrf2 dependent gene products and inhibit the Keap1–Nrf2 protein–protein Interaction</article-title>
<source/>J Med Chem
          <volume>58</volume>
<year>2015</year>
<fpage>7186</fpage>
<lpage>7194</lpage>
<pub-id pub-id-type="pmid">26348784</pub-id>
</element-citation>
</ref>
<ref id="bib60">
<label>60</label>
<element-citation id="sref60" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>East</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Fagiani</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Crosby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Georgakopoulos</surname>
<given-names>N.D.</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Schaap</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>PMI: a ΔΨ-independent pharmacological regulator of mitophagy</article-title>
<source/>Chem Biol
          <volume>21</volume>
<year>2014</year>
<fpage>1585</fpage>
<lpage>1596</lpage>
<pub-id pub-id-type="pmid">25455860</pub-id>
</element-citation>
</ref>
<ref id="bib61">
<label>61</label>
<element-citation id="sref61" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Izzo</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bravo-San Pedro</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Sica</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kroemer</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Galluzzi</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Mitochondrial permeability transition: new findings and persisting uncertainties</article-title>
<source/>Trends Cell Biol
          <volume>26</volume>
<year>2016</year>
<fpage>655</fpage>
<lpage>667</lpage>
<pub-id pub-id-type="pmid">27161573</pub-id>
</element-citation>
</ref>
<ref id="bib62">
<element-citation id="sref62" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Talalay</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Posner</surname>
<given-names>G.H.</given-names>
</name>
</person-group>
<article-title>A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure</article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>89</volume>
<year>1992</year>
<fpage>2399</fpage>
<lpage>2403</lpage>
<pub-id pub-id-type="pmid">1549603</pub-id>
</element-citation>
<note>
<p>Isolation of sulforaphane as the principal inducer of the prototypical Nrf2 target enzyme NQO1 from broccoli.</p>
</note>
</ref>
<ref id="bib63">
<label>63</label>
<element-citation id="sref63" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Palliyaguru</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Kensler</surname>
<given-names>T.W.</given-names>
</name>
</person-group>
<article-title>Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane</article-title>
<source/>Semin Oncol
          <volume>43</volume>
<year>2016</year>
<fpage>146</fpage>
<lpage>153</lpage>
<pub-id pub-id-type="pmid">26970133</pub-id>
</element-citation>
</ref>
<ref id="bib64">
<label>64</label>
<element-citation id="sref64" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greco</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fiskum</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Brain mitochondria from rats treated with sulforaphane are resistant to redox-regulated permeability transition</article-title>
<source/>J Bioenerg Biomembr
          <volume>42</volume>
<year>2010</year>
<fpage>491</fpage>
<lpage>497</lpage>
<pub-id pub-id-type="pmid">21061051</pub-id>
</element-citation>
</ref>
<ref id="bib65">
<label>65</label>
<element-citation id="sref65" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joshi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>The Nrf2–ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases</article-title>
<source/>Recent Pat CNS Drug Discov
          <volume>7</volume>
<year>2012</year>
<fpage>218</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="pmid">22742419</pub-id>
</element-citation>
</ref>
<ref id="bib66">
<label>66</label>
<element-citation id="sref66" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Nrf2-a therapeutic target for the treatment of neurodegenerative diseases</article-title>
<source/>Free Radic Biol Med
          <volume>88</volume>
<year>2015</year>
<fpage>253</fpage>
<lpage>267</lpage>
<pub-id pub-id-type="pmid">26281945</pub-id>
</element-citation>
</ref>
<ref id="bib67">
<element-citation id="sref67" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Vargas</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the α-synuclein mutant (A53T) mouse model</article-title>
<source/>J Neurosci
          <volume>32</volume>
<year>2012</year>
<fpage>17775</fpage>
<lpage>17787</lpage>
<pub-id pub-id-type="pmid">23223297</pub-id>
</element-citation>
<note>
<p>Nrf2 overexpression in astrocytes provides neuroprotection in a mouse model of Parkinson's disease.</p>
</note>
</ref>
<ref id="bib68">
<label>68</label>
<element-citation id="sref68" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williamson</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Activation of the Nrf2–ARE pathway by siRNA knockdown of Keap1 reduces oxidative stress and provides partial protection from MPTP-mediated neurotoxicity</article-title>
<source/>Neurotoxicology
          <volume>33</volume>
<year>2012</year>
<fpage>272</fpage>
<lpage>279</lpage>
<pub-id pub-id-type="pmid">22342405</pub-id>
</element-citation>
</ref>
<ref id="bib69">
<element-citation id="sref69" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>Vargas</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Pani</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Smeyne</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Kan</surname>
<given-names>Y.W.</given-names>
</name>
</person-group>
<article-title>Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte</article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>106</volume>
<year>2009</year>
<fpage>2933</fpage>
<lpage>2938</lpage>
<pub-id pub-id-type="pmid">19196989</pub-id>
</element-citation>
<note>
<p>Astrocytic Nrf2 provides neuroprotection in a mouse model of Parkinson's disease.</p>
</note>
</ref>
<ref id="bib70">
<element-citation id="sref70" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jazwa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rojo</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Innamorato</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Hesse</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fernandez-Ruiz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cuadrado</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism</article-title>
<source/>Antioxid Redox Signal
          <volume>14</volume>
<year>2011</year>
<fpage>2347</fpage>
<lpage>2360</lpage>
<pub-id pub-id-type="pmid">21254817</pub-id>
</element-citation>
<note>
<p>The Nrf2 inducer sulforaphane is neuroprotective in a mouse model of Parkinson's disease.</p>
</note>
</ref>
<ref id="bib71">
<label>71</label>
<element-citation id="sref71" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lastres-Becker</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ulusoy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Innamorato</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rabano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kirik</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease</article-title>
<source/>Hum Mol Genet
          <volume>21</volume>
<year>2012</year>
<fpage>3173</fpage>
<lpage>3192</lpage>
<pub-id pub-id-type="pmid">22513881</pub-id>
</element-citation>
</ref>
<ref id="bib72">
<element-citation id="sref72" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rojo</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Innamorato</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Martin-Moreno</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>De Ceballos</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cuadrado</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease</article-title>
<source/>Glia
          <volume>58</volume>
<year>2010</year>
<fpage>588</fpage>
<lpage>598</lpage>
<pub-id pub-id-type="pmid">19908287</pub-id>
</element-citation>
<note>
<p>Nrf2 regulates neuroinflammation in a mouse model of Parkinson's disease.</p>
</note>
</ref>
<ref id="bib73">
<label>73</label>
<element-citation id="sref73" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abeti</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Uzun</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Renganathan</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Honda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pook</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Giunti</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Targeting lipid peroxidation and mitochondrial imbalance in Friedreich's ataxia</article-title>
<source/>Pharmacol Res
          <volume>99</volume>
<year>2015</year>
<fpage>344</fpage>
<lpage>350</lpage>
<pub-id pub-id-type="pmid">26141703</pub-id>
</element-citation>
</ref>
<ref id="bib74">
<label>74</label>
<element-citation id="sref74" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>H.V.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Ehrlich</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model</article-title>
<source/>Amyloid
          <volume>20</volume>
<year>2013</year>
<fpage>7</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="pmid">23253046</pub-id>
</element-citation>
</ref>
<ref id="bib75">
<label>75</label>
<element-citation id="sref75" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsvetkov</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Arrasate</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Barmada</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Shaby</surname>
<given-names>B.A.</given-names>
</name>
</person-group>
<article-title>Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration</article-title>
<source/>Nat Chem Biol
          <volume>9</volume>
<year>2013</year>
<fpage>586</fpage>
<lpage>592</lpage>
<pub-id pub-id-type="pmid">23873212</pub-id>
</element-citation>
</ref>
<ref id="bib76">
<element-citation id="sref76" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quinti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Casale</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Moniot</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pais</surname>
<given-names>T.F.</given-names>
</name>
<name>
<surname>Kaltenbach</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Pallos</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>SIRT2- and NRF2-targeting thiazole-containing compound with therapeutic activity in Huntington's disease models</article-title>
<source/>Cell Chem Biol
          <volume>23</volume>
<year>2016</year>
<fpage>849</fpage>
<lpage>861</lpage>
<pub-id pub-id-type="pmid">27427231</pub-id>
</element-citation>
<note>
<p>Identification of a new class of thiazole Nrf2 activators with therapeutic potential in models of Huntington's disease.</p>
</note>
</ref>
<ref id="bib77">
<label>77</label>
<element-citation id="sref77" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xin</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>An overview of the molecular mechanisms and novel roles of Nrf2 in neurodegenerative disorders</article-title>
<source/>Cytokine Growth Factor Rev
          <volume>26</volume>
<year>2015</year>
<fpage>47</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="pmid">25280871</pub-id>
</element-citation>
</ref>
<ref id="bib78">
<label>78</label>
<element-citation id="sref78" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawalec</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mikrut</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wisniewska</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis</article-title>
<source/>Curr Neuropharmacol
          <volume>12</volume>
<year>2014</year>
<fpage>256</fpage>
<lpage>268</lpage>
<pub-id pub-id-type="pmid">24851089</pub-id>
</element-citation>
</ref>
<ref id="bib79">
<label>79</label>
<element-citation id="sref79" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bomprezzi</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview</article-title>
<source/>Ther Adv Neurol Disord
          <volume>8</volume>
<year>2015</year>
<fpage>20</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="pmid">25584071</pub-id>
</element-citation>
</ref>
<ref id="bib80">
<label>80</label>
<element-citation id="sref80" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lovestone</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Boada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dubois</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hull</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rinne</surname>
<given-names>J.O.</given-names>
</name>
<name>
<surname>Huppertz</surname>
<given-names>H.J.</given-names>
</name>
</person-group>
<article-title>A phase II trial of tideglusib in Alzheimer's disease</article-title>
<source/>J Alzheimers Dis
          <volume>45</volume>
<year>2015</year>
<fpage>75</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="pmid">25537011</pub-id>
</element-citation>
</ref>
<ref id="bib81">
<element-citation id="sref81" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Connors</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Macklin</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Fahey</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Talalay</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Sulforaphane treatment of autism spectrum disorder (ASD)</article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>111</volume>
<year>2014</year>
<fpage>15550</fpage>
<lpage>15555</lpage>
<pub-id pub-id-type="pmid">25313065</pub-id>
</element-citation>
<note>
<p>The Nrf2 inducer sulforaphane improves clinical outcomes in autism.</p>
</note>
</ref>
<ref id="bib82">
<label>82</label>
<element-citation id="sref82" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Napoli</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hertz-Picciotto</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Giulivi</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Deficits in bioenergetics and impaired immune response in granulocytes from children with autism</article-title>
<source/>Pediatrics
          <volume>133</volume>
<year>2014</year>
<fpage>e1405</fpage>
<lpage>1410</lpage>
<pub-id pub-id-type="pmid">24753527</pub-id>
</element-citation>
</ref>
<ref id="bib83">
<label>83</label>
<element-citation id="sref83" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armah</surname>
<given-names>C.N.</given-names>
</name>
<name>
<surname>Traka</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Dainty</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Defernez</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Janssens</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>A diet rich in high-glucoraphanin broccoli interacts with genotype to reduce discordance in plasma metabolite profiles by modulating mitochondrial function</article-title>
<source/>Am J Clin Nutr
          <volume>98</volume>
<year>2013</year>
<fpage>712</fpage>
<lpage>722</lpage>
<pub-id pub-id-type="pmid">23964055</pub-id>
</element-citation>
</ref>
<ref id="bib84">
<label>84</label>
<element-citation id="sref84" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calabrese</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Cornelius</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dinkova-Kostova</surname>
<given-names>A.T.</given-names>
</name>
<name>
<surname>Iavicoli</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Di Paola</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Koverech</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Cellular stress responses, hormetic phytochemicals and vitagenes in aging and longevity</article-title>
<source/>Biochim Biophys Acta
          <volume>1822</volume>
<year>2012</year>
<fpage>753</fpage>
<lpage>783</lpage>
<pub-id pub-id-type="pmid">22108204</pub-id>
</element-citation>
</ref>
<ref id="bib85">
<label>85</label>
<element-citation id="sref85" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Finkel</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Mitohormesis</article-title>
<source/>Cell Metab
          <volume>19</volume>
<year>2014</year>
<fpage>757</fpage>
<lpage>766</lpage>
<pub-id pub-id-type="pmid">24561260</pub-id>
</element-citation>
</ref>
<ref id="bib86">
<label>86</label>
<element-citation id="sref86" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindsay</surname>
<given-names>D.G.</given-names>
</name>
</person-group>
<article-title>Nutrition, hormetic stress and health</article-title>
<source/>Nutr Res Rev
          <volume>18</volume>
<year>2005</year>
<fpage>249</fpage>
<lpage>258</lpage>
<pub-id pub-id-type="pmid">19079909</pub-id>
</element-citation>
</ref>
<ref id="bib87">
<label>87</label>
<element-citation id="sref87" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calabrese</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Cornelius</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mancuso</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pennisi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Calafato</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bellia</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity</article-title>
<source/>Neurochem Res
          <volume>33</volume>
<year>2008</year>
<fpage>2444</fpage>
<lpage>2471</lpage>
<pub-id pub-id-type="pmid">18629638</pub-id>
</element-citation>
</ref>
<ref id="bib88">
<label>88</label>
<element-citation id="sref88" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hine</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>NRF2 and the phase II response in acute stress resistance induced by dietary restriction</article-title>
<source/>J Clin Exp Pathol
          <year>2012</year>
<fpage>S4</fpage>
</element-citation>
</ref>
<ref id="bib89">
<label>89</label>
<element-citation id="sref89" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinbaugh</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Narasimhan</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Robida-Stubbs</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Moronetti Mazzeo</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Dreyfuss</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Hourihan</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Lipid-mediated regulation of SKN-1/Nrf in response to germ cell absence</article-title>
<source/>Elife
          <year>2015</year>
<fpage>4</fpage>
</element-citation>
</ref>
<ref id="bib90">
<label>90</label>
<element-citation id="sref90" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kenyon</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Roles for ROS and hydrogen sulfide in the longevity response to germline loss in <italic>Caenorhabditis elegans</italic></article-title>
<source/>Proc Natl Acad Sci U S A
          <volume>113</volume>
<year>2016</year>
<fpage>E2832</fpage>
<lpage>2841</lpage>
<pub-id pub-id-type="pmid">27140632</pub-id>
</element-citation>
</ref>
<ref id="bib91">
<label>91</label>
<element-citation id="sref91" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kodera</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hirata</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Blackwell</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Mizunuma</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Natural thioallyl compounds increase oxidative stress resistance and lifespan in <italic>Caenorhabditis elegans</italic> by modulating SKN-1/Nrf</article-title>
<source/>Sci Rep
          <volume>6</volume>
<year>2016</year>
<fpage>21611</fpage>
<pub-id pub-id-type="pmid">26899496</pub-id>
</element-citation>
</ref>
<ref id="bib92">
<element-citation id="sref92" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lynn</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Paek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Curran</surname>
<given-names>S.P.</given-names>
</name>
</person-group>
<article-title>SKN-1 and Nrf2 couples proline catabolism with lipid metabolism during nutrient deprivation</article-title>
<source/>Nat Commun
          <volume>5</volume>
<year>2014</year>
<fpage>5048</fpage>
<pub-id pub-id-type="pmid">25284427</pub-id>
</element-citation>
<note>
<p>Nrf2 couples proline catabolism with lipid metabolism.</p>
</note>
</ref>
<ref id="bib93">
<label>93</label>
<element-citation id="sref93" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castillo-Quan</surname>
<given-names>J.I.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kinghorn</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Ivanov</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Tain</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Slack</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Lithium promotes longevity through GSK3/NRF2-dependent hormesis</article-title>
<source/>Cell Rep
          <volume>15</volume>
<year>2016</year>
<fpage>638</fpage>
<lpage>650</lpage>
<pub-id pub-id-type="pmid">27068460</pub-id>
</element-citation>
</ref>
<ref id="bib94">
<label>94</label>
<element-citation id="sref94" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wakabayashi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wakabayashi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Motohashi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Noda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation</article-title>
<source/>Nat Genet
          <volume>35</volume>
<year>2003</year>
<fpage>238</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="pmid">14517554</pub-id>
</element-citation>
</ref>
<ref id="bib95">
<label>95</label>
<element-citation id="sref95" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsakiri</surname>
<given-names>E.N.</given-names>
</name>
<name>
<surname>Sykiotis</surname>
<given-names>G.P.</given-names>
</name>
<name>
<surname>Papassideri</surname>
<given-names>I.S.</given-names>
</name>
<name>
<surname>Terpos</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Dimopoulos</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Gorgoulis</surname>
<given-names>V.G.</given-names>
</name>
</person-group>
<article-title>Proteasome dysfunction in <italic>Drosophila</italic> signals to an Nrf2-dependent regulatory circuit aiming to restore proteostasis and prevent premature aging</article-title>
<source/>Aging Cell
          <volume>12</volume>
<year>2013</year>
<fpage>802</fpage>
<lpage>813</lpage>
<pub-id pub-id-type="pmid">23738891</pub-id>
</element-citation>
</ref>
<ref id="bib96">
<element-citation id="sref96" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corenblum</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Remley</surname>
<given-names>Q.W.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Harder</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.D.</given-names>
</name>
</person-group>
<article-title>Reduced Nrf2 expression mediates the decline in neural stem cell function during a critical middle-age period</article-title>
<source/>Aging Cell
          <volume>15</volume>
<year>2016</year>
<fpage>725</fpage>
<lpage>736</lpage>
<pub-id pub-id-type="pmid">27095375</pub-id>
</element-citation>
<note>
<p>Reduced Nrf2 expression mediates the decline in neural stem cell function.</p>
</note>
</ref>
<ref id="bib97">
<element-citation id="sref97" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khacho</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Svoboda</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Azzi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>MacLaurin</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Meghaizel</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Mitochondrial dynamics impacts stem cell identity and fate decisions by regulating a nuclear transcriptional program</article-title>
<source/>Cell Stem Cell
          <volume>19</volume>
<year>2016</year>
<fpage>232</fpage>
<lpage>247</lpage>
<pub-id pub-id-type="pmid">27237737</pub-id>
</element-citation>
<note>
<p>** Mitochondrial dynamics affects stem cell fate decisions by driving a dual program to suppress self-renewal and promote differentiation via Nrf2 signalling.</p>
</note>
</ref>
<ref id="bib98">
<element-citation id="sref98" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hawkins</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Joy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Delhove</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Kotiadis</surname>
<given-names>V.N.</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fitzpatrick</surname>
<given-names>L.M.</given-names>
</name>
</person-group>
<article-title>NRF2 orchestrates the metabolic shift during induced pluripotent stem cell reprogramming</article-title>
<source/>Cell Rep
          <volume>14</volume>
<year>2016</year>
<fpage>1883</fpage>
<lpage>1891</lpage>
<pub-id pub-id-type="pmid">26904936</pub-id>
</element-citation>
<note>
<p>Nrf2 orchestrates the metabolic shift during induced pluripotent stem cell reprogramming.</p>
</note>
</ref>
<ref id="bib99">
<label>99</label>
<element-citation id="sref99" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ghebre</surname>
<given-names>Y.T.</given-names>
</name>
<name>
<surname>Cooke</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Optimal ROS signaling is critical for nuclear reprogramming</article-title>
<source/>Cell Rep
          <volume>15</volume>
<year>2016</year>
<fpage>919</fpage>
<lpage>925</lpage>
<pub-id pub-id-type="pmid">27117405</pub-id>
</element-citation>
</ref>
<ref id="bib100">
<element-citation id="sref100" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tao</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kahr</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>Morikawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rahmani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Heallen</surname>
<given-names>T.R.</given-names>
</name>
</person-group>
<article-title>Pitx2 promotes heart repair by activating the antioxidant response after cardiac injury</article-title>
<source/>Nature
          <volume>534</volume>
<year>2016</year>
<fpage>119</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="pmid">27251288</pub-id>
</element-citation>
<note>
<p>Nrf2 signalling is critical for heart repair.</p>
</note>
</ref>
<ref id="bib101">
<element-citation id="sref101" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kubben</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Voss</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Repression of the antioxidant Nrf2 pathway in premature aging</article-title>
<source/>Cell
          <volume>165</volume>
<year>2016</year>
<fpage>1361</fpage>
<lpage>1374</lpage>
<pub-id pub-id-type="pmid">27259148</pub-id>
</element-citation>
<note>
<p>Nrf2 signalling is repressed in premature aging.</p>
</note>
</ref>
<ref id="bib102">
<label>102</label>
<element-citation id="sref102" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gabriel</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Roedl</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>L.B.</given-names>
</name>
<name>
<surname>Djabali</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts</article-title>
<source/>Aging Cell
          <volume>14</volume>
<year>2015</year>
<fpage>78</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="pmid">25510262</pub-id>
</element-citation>
</ref>
<ref id="bib103">
<label>103</label>
<element-citation id="sref103" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sazanov</surname>
<given-names>L.A.</given-names>
</name>
</person-group>
<article-title>A giant molecular proton pump: structure and mechanism of respiratory complex I</article-title>
<source/>Nat Rev Mol Cell Biol
          <volume>16</volume>
<year>2015</year>
<fpage>375</fpage>
<lpage>388</lpage>
<pub-id pub-id-type="pmid">25991374</pub-id>
</element-citation>
</ref>
<ref id="bib104">
<label>104</label>
<element-citation id="sref104" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Clifton</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Dash</surname>
<given-names>P.K.</given-names>
</name>
</person-group>
<article-title>Sulforaphane enhances aquaporin-4 expression and decreases cerebral edema following traumatic brain injury</article-title>
<source/>J Neurosci Res
          <volume>82</volume>
<year>2005</year>
<fpage>499</fpage>
<lpage>506</lpage>
<pub-id pub-id-type="pmid">16211562</pub-id>
</element-citation>
</ref>
<ref id="bib105">
<label>105</label>
<element-citation id="sref105" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Redell</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Dash</surname>
<given-names>P.K.</given-names>
</name>
</person-group>
<article-title>Enhancing expression of Nrf2-driven genes protects the blood brain barrier after brain injury</article-title>
<source/>J Neurosci
          <volume>27</volume>
<year>2007</year>
<fpage>10240</fpage>
<lpage>10248</lpage>
<pub-id pub-id-type="pmid">17881530</pub-id>
</element-citation>
</ref>
<ref id="bib106">
<label>106</label>
<element-citation id="sref106" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>The role of Nrf2 signaling in the regulation of antioxidants and detoxifying enzymes after traumatic brain injury in rats and mice</article-title>
<source/>Acta Pharmacol Sin
          <volume>31</volume>
<year>2010</year>
<fpage>1421</fpage>
<lpage>1430</lpage>
<pub-id pub-id-type="pmid">20953205</pub-id>
</element-citation>
</ref>
<ref id="bib107">
<label>107</label>
<element-citation id="sref107" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Role of the Nrf2–ARE pathway in early brain injury after experimental subarachnoid hemorrhage</article-title>
<source/>J Neurosci Res
          <volume>89</volume>
<year>2011</year>
<fpage>515</fpage>
<lpage>523</lpage>
<pub-id pub-id-type="pmid">21259333</pub-id>
</element-citation>
</ref>
<ref id="bib108">
<label>108</label>
<element-citation id="sref108" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.L.</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>H.X.</given-names>
</name>
</person-group>
<article-title>Sulforaphane attenuates matrix metalloproteinase-9 expression following spinal cord injury in mice</article-title>
<source/>Ann Clin Lab Sci
          <volume>40</volume>
<year>2010</year>
<fpage>354</fpage>
<lpage>360</lpage>
<pub-id pub-id-type="pmid">20947810</pub-id>
</element-citation>
</ref>
<ref id="bib109">
<label>109</label>
<element-citation id="sref109" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Transcription factor Nrf2 protects the spinal cord from inflammation produced by spinal cord injury</article-title>
<source/>J Surg Res
          <volume>170</volume>
<year>2011</year>
<fpage>e105</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="pmid">21764072</pub-id>
</element-citation>
</ref>
<ref id="bib110">
<label>110</label>
<element-citation id="sref110" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>de Rivero Vaccari</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Diaz</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>German</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Marcillo</surname>
<given-names>A.E.</given-names>
</name>
</person-group>
<article-title>Activation of the nuclear factor e2-related factor 2/antioxidant response element pathway is neuroprotective after spinal cord injury</article-title>
<source/>J Neurotrauma
          <volume>29</volume>
<year>2012</year>
<fpage>936</fpage>
<lpage>945</lpage>
<pub-id pub-id-type="pmid">21806470</pub-id>
</element-citation>
</ref>
<ref id="bib111">
<label>111</label>
<element-citation id="sref111" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benedict</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Mountney</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hurtado</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bryan</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Schnaar</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Dinkova-Kostova</surname>
<given-names>A.T.</given-names>
</name>
</person-group>
<article-title>Neuroprotective effects of sulforaphane after contusive spinal cord injury</article-title>
<source/>J Neurotrauma
          <volume>29</volume>
<year>2012</year>
<fpage>2576</fpage>
<lpage>2586</lpage>
<pub-id pub-id-type="pmid">22853439</pub-id>
</element-citation>
</ref>
<ref id="bib112">
<label>112</label>
<element-citation id="sref112" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kobori</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Aronowski</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dash</surname>
<given-names>P.K.</given-names>
</name>
</person-group>
<article-title>Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents</article-title>
<source/>Neurosci Lett
          <volume>393</volume>
<year>2006</year>
<fpage>108</fpage>
<lpage>112</lpage>
<pub-id pub-id-type="pmid">16233958</pub-id>
</element-citation>
</ref>
<ref id="bib113">
<label>113</label>
<element-citation id="sref113" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Innamorato</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Jazwa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rojo</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fernandez-Ruiz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Grochot-Przeczek</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1</article-title>
<source/>PLoS One
          <volume>5</volume>
<year>2010</year>
<fpage>e11838</fpage>
<pub-id pub-id-type="pmid">20676377</pub-id>
</element-citation>
</ref>
<ref id="bib114">
<label>114</label>
<element-citation id="sref114" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morroni</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tarozzi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sita</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bolondi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zolezzi Moraga</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Cantelli-Forti</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease</article-title>
<source/>Neurotoxicology
          <volume>36</volume>
<year>2013</year>
<fpage>63</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="pmid">23518299</pub-id>
</element-citation>
</ref>
<ref id="bib115">
<label>115</label>
<element-citation id="sref115" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Sulforaphane protects against rotenone-induced neurotoxicity in vivo: involvement of the mTOR, Nrf2, and autophagy pathways</article-title>
<source/>Sci Rep
          <volume>6</volume>
<year>2016</year>
<fpage>32206</fpage>
<pub-id pub-id-type="pmid">27553905</pub-id>
</element-citation>
</ref>
<ref id="bib116">
<label>116</label>
<element-citation id="sref116" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santana-Martinez</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Galvan-Arzate</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hernandez-Pando</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chanez-Cardenas</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Avila-Chavez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lopez-Acosta</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Sulforaphane reduces the alterations induced by quinolinic acid: modulation of glutathione levels</article-title>
<source/>Neuroscience
          <volume>272</volume>
<year>2014</year>
<fpage>188</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="pmid">24814729</pub-id>
</element-citation>
</ref>
<ref id="bib117">
<label>117</label>
<mixed-citation id="sref117" publication-type="other">Luis-Garcia ER, Limon-Pacheco JH, Serrano-Garcia N, Hernandez-Perez AD, Pedraza-Chaverri J, Orozco-Ibarra M: Sulforaphane prevents quinolinic acid-induced mitochondrial dysfunction in rat striatum. J Biochem Mol Toxicol 2016; (in press).</mixed-citation>
</ref>
<ref id="bib118">
<label>118</label>
<element-citation id="sref118" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin-de-Saavedra</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Budni</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cunha</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Gomez-Rangel</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lorrio</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Del Barrio</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Nrf2 participates in depressive disorders through an anti-inflammatory mechanism</article-title>
<source/>Psychoneuroendocrinology
          <volume>38</volume>
<year>2013</year>
<fpage>2010</fpage>
<lpage>2022</lpage>
<pub-id pub-id-type="pmid">23623252</pub-id>
</element-citation>
</ref>
<ref id="bib119">
<label>119</label>
<element-citation id="sref119" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Sulforaphane produces antidepressant- and anxiolytic-like effects in adult mice</article-title>
<source/>Behav Brain Res
          <volume>301</volume>
<year>2016</year>
<fpage>55</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="pmid">26721468</pub-id>
</element-citation>
</ref>
<ref id="bib120">
<label>120</label>
<element-citation id="sref120" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Ishima</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>Role of Keap1–Nrf2 signaling in depression and dietary intake of glucoraphanin confers stress resilience in mice</article-title>
<source/>Sci Rep
          <volume>6</volume>
<year>2016</year>
<fpage>30659</fpage>
<pub-id pub-id-type="pmid">27470577</pub-id>
</element-citation>
</ref>
<ref id="bib121">
<label>121</label>
<element-citation id="sref121" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>X.H.</given-names>
</name>
</person-group>
<article-title>Sulforaphane ameliorates the development of experimental autoimmune encephalomyelitis by antagonizing oxidative stress and Th17-related inflammation in mice</article-title>
<source/>Exp Neurol
          <volume>250</volume>
<year>2013</year>
<fpage>239</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="pmid">24120440</pub-id>
</element-citation>
</ref>
<ref id="bib122">
<label>122</label>
<element-citation id="sref122" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giacoppo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Galuppo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Iori</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>De Nicola</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Cassata</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bramanti</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Protective role of (<italic>RS</italic>)-glucoraphanin bioactivated with myrosinase in an experimental model of multiple sclerosis</article-title>
<source/>CNS Neurosci Ther
          <volume>19</volume>
<year>2013</year>
<fpage>577</fpage>
<lpage>584</lpage>
<pub-id pub-id-type="pmid">23638842</pub-id>
</element-citation>
</ref>
</ref-list>
<ack id="ack0010">
<title>Acknowledgments</title>
<p>We thank Troy Faithfull for critical reading of the manuscript. We are extremely grateful to <funding-source id="gs1">Cancer Research UK</funding-source> (C20953/A18644), the <funding-source id="gs2">Biotechnology and Biological Sciences Research Council</funding-source> (BB/J007498/1), <funding-source id="gs3">Reata Pharmaceuticals</funding-source>, the <funding-source id="gs4">Academy of Finland</funding-source>, the <funding-source id="gs5">European Research Council</funding-source>, <funding-source id="gs6">Tampere University Hospital Medical Research Fund</funding-source> and <funding-source id="gs7">Sigrid Juselius Foundation</funding-source> for financial support.</p>
</ack>
</back>
<floats-group>
<fig id="fig1">
<label>Figure 1</label>
<caption>
<p><bold>Regulation of Nrf2 under homeostatic conditions</bold>. Nrf2 is a short-lived protein that is continuously targeted for ubiquitination and proteasomal degradation. Three known ubiquitin ligase systems mediate the degradation of Nrf2: Kelch-like ECH associated protein 1 (Keap1), a substrate adaptor protein for Cullin3 (Cul3)/Rbx1-based Cullin–RING E3 ubiquitin ligase and a cysteine-based sensor for Nrf2 inducers; β-transducin repeat-containing protein (β-TrCP), a substrate adaptor for Skp1–Cullin1 (Cul1)/Rbx1-based Cullin–RING E3 ubiquitin ligase; and the E3 ubiquitin ligase Hrd1 which resides in the endoplasmic reticulum (ER). The relative contributions of these systems towards the degradation of Nrf2 depend on the specific conditions. Degradation mediated by Keap1 requires reduced state of its cysteine sensors. Degradation mediated by β-TrCP requires prior phosphorylation of Nrf2 by glycogen synthase kinase 3 (GSK3). Degradation mediated by Hrd1 occurs during ER stress.</p>
</caption>
<alt-text id="alttext0010">Figure 1</alt-text>
<graphic xlink:href="gr1"></graphic>
</fig>
<fig id="fig2">
<label>Figure 2</label>
<caption>
<p><bold>Nrf2 affects mitochondrial function at multiple levels</bold>. Nrf2 activation increases the mitochondrial membrane potential (ΔΨ), the availability of substrates for respiration, and ATP production. Nrf2 positively regulates the levels of NADPH by enhancing the expression of genes encoding glucose-6-phosphate dehydrogenase (G6PD), the enzymes of the pentose phosphate pathway (PPP), malic enzyme 1 (ME1) and isocitrate dehydrogenase 1 (IDH1). In addition to NADPH, ME1 regenerates pyruvate, which can cycle back to the mitochondria. Nrf2 also regulates the levels of GSH by enhancing the expression of genes encoding enzymes involved in its biosynthesis and regeneration from its oxidized form, GSSG, including glutathione reductase (GR). Nrf2 negatively regulates ATP-citrate lyase (ACL), acetyl-CoA carboxylase, fatty acid synthase, and stearoyl CoA desaturase, four critical enzymes involved in fatty acid synthesis (FAS). A decrease in the levels of malonyl-CoA may increase mitochondrial fatty acid oxidation (FAO) by relieving its inhibitory function on carnitine palmitoyltransferase 1 (CPT1), which mediates the transport of long-chain fatty acids into the mitochondria. The red and the blue colors indicate positive and negative regulation by Nrf2, respectively. The presentation of the structure of each respiratory complex is adapted from reference <xref ref-type="bibr" rid="bib103">[103]</xref>. IMS, mitochondrial intermembrane space.</p>
</caption>
<alt-text id="alttext0015">Figure 2</alt-text>
<graphic xlink:href="gr2"></graphic>
</fig>
<fig id="fig3">
<label>Figure 3</label>
<caption>
<p><bold>Examples of small-molecule Nrf2 activators that improve mitochondrial function and integrity</bold>. Chemical structures of 1-(3-iodophenyl)-4-(3-nitrophenyl)-1,2,3-triazole (PMI), 1-isothiocyanato-(4<italic>R</italic>)-(methylsulfinyl)butane (sulforaphane), N-(11-cyano-2,2,6a,6b,9,9,12a-heptmethyl-10,14-dioxo-1,3,4,5,6a,6b,7,8,8a,9,10,12a,14,14a,14b-hexadecahydro-2H-picen-4a-yl)-2-2-difluoro-propionamide (RTA-408, Omaveloxolone) and dimethyl fumarate (BG-12, Tecfidera).</p>
</caption>
<alt-text id="alttext0020b">Figure 3</alt-text>
<graphic xlink:href="gr3"></graphic>
</fig>
<table-wrap id="tbl1" position="float">
<label>Table 1</label>
<caption>
<p>Protective Activity of Sulforaphane and Its Glucoraphanin Precursor in Rodent Models of Neurological Conditions.</p>
</caption>
<alt-text id="alttext0025">Table 1</alt-text>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th>Condition/disease</th>
<th>Species/strain</th>
<th>Damaging agent</th>
<th>Sulforaphane dose</th>
<th>Efficacy endpoints</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain injury</td>
<td>Rat ♂<break></break>Sprague Dawley</td>
<td>Controlled cortical impact</td>
<td>5 mg/kg, i.p., 6 h post-injury</td>
<td>Increase in AQP4 in penumbra; increase in GPx in cortex; increase in GSTα3 and HO-1 in brain microvessels; decrease in loss of tight junction proteins and endothelial cells; decrease in blood-brain barrier permeability and cerebral edema</td>
<td>Zhao et al. (2005, 2007) <xref ref-type="bibr" rid="bib104">104</xref>, <xref ref-type="bibr" rid="bib105">105</xref></td>
</tr>
<tr>
<td>Brain injury</td>
<td>Rat ♂ Sprague Dawley</td>
<td>Controlled cortical impact</td>
<td>5 mg/kg, i.p., 15 min post-injury</td>
<td>Increase in Nrf2, NQO1 and HO-1 in cortex; decreased oxidative damage to lipids, proteins and DNA; decreased brain contusion volume and cortical neuronal death; improved neurologic function</td>
<td>Hong et al. (2010) <xref ref-type="bibr" rid="bib106">[106]</xref></td>
</tr>
<tr>
<td>Brain injury</td>
<td>Mouse ♂<break></break>C57BL/6<break></break>WT and Nrf2<sup>−/−</sup></td>
<td>Controlled cortical impact</td>
<td>5 mg/kg, i.p., 6 h post-injury</td>
<td>Decrease in blood-brain barrier permeability in WT mice; Nrf2<sup>−/−</sup> mice more sensitive than WT mice &amp; no protection by SFN</td>
<td>Zhao et al. (2007) <xref ref-type="bibr" rid="bib105">[105]</xref></td>
</tr>
<tr>
<td>Brain injury</td>
<td>Mouse ♂<break></break>ICR<break></break>WT and Nrf2<sup>−/−</sup></td>
<td>Controlled cortical impact</td>
<td>5 mg/kg, i.p., 15 min post-injury</td>
<td>Nrf2<sup>−/−</sup> mice more sensitive than WT mice &amp; no protection by SFN</td>
<td>Hong et al. (2010) <xref ref-type="bibr" rid="bib106">[106]</xref></td>
</tr>
<tr>
<td>Brain injury</td>
<td>Rat ♂<break></break>Wistar</td>
<td>Subarachnoid hemorrhage</td>
<td>5 mg/kg, i.p., 30 min, 12 h, and 36 h after blood injection</td>
<td>Increase in Nrf2, NQO1, GSTα1 and HO-1 in cortex; decrease in cerebral edema, blood-brain barrier impairment, cortical apoptosis, and motor deficits</td>
<td>Chen et al. (2011) <xref ref-type="bibr" rid="bib107">[107]</xref></td>
</tr>
<tr>
<td>Spinal cord injury</td>
<td>Mouse ♂<break></break>ICR<break></break>WT and Nrf2<sup>−/−</sup></td>
<td>Contusion injury (vascular clip, 10 g)</td>
<td>5 mg/kg, i.p.,<break></break>1 h after injury</td>
<td>Decrease in MMP9 and TNFα, vascular permeability changes, inflammatory damage, histologic injury, dying neurons count, and spinal cord edema; enhanced hindlimb locomotor function;<break></break>Nrf2<sup>−/−</sup> mice more sensitive than WT mice &amp; no protection by SFN</td>
<td>Mao et al. (2010, 2011) <xref ref-type="bibr" rid="bib108">108</xref>, <xref ref-type="bibr" rid="bib109">109</xref></td>
</tr>
<tr>
<td>Spinal cord injury</td>
<td>Rat ♀<break></break>Fischer</td>
<td>Contusion injury (weight drop, 10 g)</td>
<td>5 mg/kg, i.p., 15 min after injury, then once a day for 3 days</td>
<td>Increase in Nrf2 and GCLC in spinal cord 1 day after injury; decrease in IL-1β, TNFα, IκBα phosphorylation, and contusion volume; improvement in coordination</td>
<td>Wang et al. (2012) <xref ref-type="bibr" rid="bib110">[110]</xref></td>
</tr>
<tr>
<td>Spinal cord injury</td>
<td>Rat ♀<break></break>Sprague-Dawley</td>
<td>Contusion injury (200 kdyn)</td>
<td>10 or 50 mg/kg, i.p., 10 min and 72 h after injury</td>
<td>Increase in NQO1 and HO-1, and decrease in MMP9 in spinal cord 4 h after injury; decrease in urinary MIF activity; increase in serotonergic axons caudal to the lesion; enhanced hindlimb locomotor function</td>
<td>Benedict et al. (2012) <xref ref-type="bibr" rid="bib111">[111]</xref></td>
</tr>
<tr>
<td>Stroke</td>
<td>Rat ♂<break></break>Long–Evans</td>
<td>Temporary common carotid/middle cerebral artery occlusion</td>
<td>5 mg/kg, i.p., 15 min post-ischemia</td>
<td>Increase in HO-1 in brain; decrease in infarct volume</td>
<td>Zhao et al. (2006) <xref ref-type="bibr" rid="bib112">[112]</xref></td>
</tr>
<tr>
<td>Alzheimer's disease</td>
<td>Mouse ♂<break></break>ICR</td>
<td>Aβ(1-40) injection, i.c.v.</td>
<td>30 mg/kg/day, i.p., from day −1 to day 4 post-Aβ</td>
<td>Decrease in impairment of working and contextual memory; no effect on amyloidogenesis</td>
<td>Kim et al. (2013) <xref ref-type="bibr" rid="bib74">[74]</xref></td>
</tr>
<tr>
<td>Parkinson's disease</td>
<td>Mouse ♂<break></break>C57BL/6<break></break>WT and Nrf2<sup>−/−</sup></td>
<td>MPTP (for 5 consecutive days starting on day 0)</td>
<td>50 mg/kg, i.p., on day −1 (2 doses, 8 h apart); then daily doses on day 1, 3 and 5</td>
<td>Increase in NQO1, HO-1, GCLC and GCLM in striatum and ventral midbrain; decrease in loss of dopaminergic neurons, astrogliosis and microgliosis; decrease in pro-inflammatory mediators (IL6 and TNFα);<break></break>Nrf2<sup>−/−</sup> mice more sensitive than WT mice &amp; no protection by SFN</td>
<td>Rojo et al. (2010), Innamoratoet al. (2010), and Jazwa et al. (2011) <xref ref-type="bibr" rid="bib70">∗70</xref>, <xref ref-type="bibr" rid="bib72">∗72</xref>, <xref ref-type="bibr" rid="bib113">113</xref></td>
</tr>
<tr>
<td>Parkinson's disease</td>
<td>Mouse ♂<break></break>C57BL6/SJL</td>
<td>MPTP</td>
<td></td>
<td>Nrf2<sup>−/−</sup> mice more sensitive than WT mice; protection by Nrf2 overexpression or Keap1 (by siRNA) downregulation</td>
<td>Chen et al. (2009) and Williamson et al. (2012) <xref ref-type="bibr" rid="bib68">68</xref>, <xref ref-type="bibr" rid="bib69">∗69</xref></td>
</tr>
<tr>
<td>Parkinson's disease</td>
<td>Mouse ♂<break></break>C57BL/6</td>
<td>6-Hydroxy-dopamine-induced lesion</td>
<td>5 mg/kg, i.p., twice a week for 4 weeks starting after lesion induction</td>
<td>Decrease in motor function deficits; decrease in degeneration of dopaminergic neurons and DNA fragmentation; increase in GSH and GR</td>
<td>Morroni et al. (2013) <xref ref-type="bibr" rid="bib114">[114]</xref></td>
</tr>
<tr>
<td>Parkinson's disease</td>
<td>Mouse ♂<break></break>C57BL/6</td>
<td>Rotenone</td>
<td>50 mg/kg, i.p., every other day before rotenone for 60 days</td>
<td>Increase in NQO1, HO-1 and LC3-II in cortex and striatum compared to rotenone treatment; decrease in rotenone-induced oxidative damage; decrease in loss of dopaminergic neurons; decrease in motor function deficits</td>
<td>Zhou et al. (2016) <xref ref-type="bibr" rid="bib115">[115]</xref></td>
</tr>
<tr>
<td>Huntington's disease</td>
<td>Rat ♂<break></break>Wistar</td>
<td>2,3-Pyridine-dicarboxylic acid (quinolinic acid)</td>
<td>5 mg/kg, i.p., 24 h and 5 min before intrastriatal infusion of quinolinic acid</td>
<td>Increase in GSH, GR, and GPx; decrease in oxidized proteins, mitochondrial dysfunction, striatal degeneration and circling behavior</td>
<td>Santana-Martínez et al. (2014) and Luis-García et al. (2016) <xref ref-type="bibr" rid="bib116">116</xref>, <xref ref-type="bibr" rid="bib117">117</xref></td>
</tr>
<tr>
<td>Depression</td>
<td>Mouse ♂<break></break>Swiss and C57BL/6<break></break>WT and Nrf2<sup>−/−</sup></td>
<td>LPS</td>
<td>1 mg/kg, i.p., for 7 consecutive days before and the day after LPS</td>
<td>Compared to WT mice, decrease in dopamine and serotonin levels in prefrontal cortex, retraction of astroglial processes, increased microgliosis and depressive phenotype of Nrf2<sup>−/−</sup> mice without LPS;<break></break>Increase in HO-1, GCLM and BDNF and decrease in iNOS by SFN in hippocampus of in WT mice with LPS;<break></break>Improved depressive-like behavior in WT mice with LPS</td>
<td>Martín-de-Saavedra et al. (2013) <xref ref-type="bibr" rid="bib118">[118]</xref></td>
</tr>
<tr>
<td>Depression</td>
<td>Mouse ♂<break></break>ICR</td>
<td>Acute stress<break></break>Chronic stress<break></break>(28 days)</td>
<td>1, 3, or 10 mg/kg/day, i.p., for 14 days<break></break>10 mg/kg/day, i.p., for 14 days starting on day 14</td>
<td>Reversal of depressive- and anxiety-like behavior<break></break>Decrease in pro-inflammatory mediators (IL6 and TNFα) and serum corticosterone and adrenocorticotropic hormone levels; reversal of depressive- and anxiety-like behavior</td>
<td>Wu et al. (2016) <xref ref-type="bibr" rid="bib119">[119]</xref></td>
</tr>
<tr>
<td>Depression</td>
<td>Mouse ♂<break></break>C57BL/6<break></break>WT and Nrf2<sup>−/−</sup></td>
<td>Repeated social defeat stress for 10 days</td>
<td>10 mg/kg, i.p.,<break></break>30 min before defeat stress<break></break>or<break></break>0.1% dietary glucoraphanin</td>
<td>Attenuation of decreased levels in Keap1, Nrf2, BDNF, p-TrkB, and depression-like behavior;<break></break>Nrf2<sup>−/−</sup> mice more sensitive than WT mice</td>
<td>Yao et al. (2016) <xref ref-type="bibr" rid="bib120">[120]</xref></td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>Mouse ♀<break></break>C57BL/6</td>
<td>(MOG)<sub>35–55</sub> immunization, followed by Pertussis toxin</td>
<td>50 mg/kg, i.p., every other day for 22 days</td>
<td>Inhibition of development and severity of experimental autoimmune encephalomyelitis; increase in HO-1 and NQO1, and decrease in oxidative stress in brain; decrease in MMP9, inflammatory infiltration and demyelination in spinal cord; improved distribution of claudin-5 and occluding; preservation of the blood–brain barrier; inhibition of antigen-specific Th17 responses and enhanced IL10 responses</td>
<td>Li et al. (2013) <xref ref-type="bibr" rid="bib121">[121]</xref></td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>Mouse ♂<break></break>C57BL/6</td>
<td>MOG35-55 immunization, followed by Pertussis toxin</td>
<td>10 mg/kg/day, i.p., myrosinase-activated glucoraphanin beginning 1 week before immunization</td>
<td>Decrease in inflammation (NFkB translocation and IL1β) and apoptosis (Bax and caspase 3) in spinal cord; protection against body weight loss</td>
<td>Giacoppo et al. (2013) <xref ref-type="bibr" rid="bib122">[122]</xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p><bold>Abbreviations:</bold> AQP4, aquaporin 4; BDNF, brain-derived neurotrophic factor; GCLC, glutamate cysteine ligase catalytic subunit; GCLM, glutamate cysteine ligase modulatory subunit; GPx, glutathione peroxidase; GSH, reduced glutathione; GST, glutathione <italic>S</italic>-transferase; HO-1, heme oxygenase 1; IκBα, nuclear factor kappa-light-chain-enhancer of activated B cells inhibitor, α; IL, interleukin; LC3, microtubule-associated protein light chain 3; LPS, lipopolysaccharide; MIF, macrophage inhibitory factor; MMP9, matrix metalloproteinase 9; MOG, myelin oligodendroglial glycoprotein peptide; MPTP, methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine; NFkB, nuclear factor kappa-light-chain-enhancer of activated B cells; NQO1, NAD(P)H:quinone oxidoreductase 1; SFN, sulforaphane; TNFα, tumor necrosis factor α; p-TrkB, phosphorylated tropomyosin-receptor-kinase B.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>